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Abstract
The glucagon-like peptide-1 receptor (GLP-1R), a key pharmacological target in type 2 dia-
betes (T2D) and obesity, undergoes rapid endocytosis after stimulation by endogenous and
therapeutic agonists. We have previously highlighted the relevance of this process in fine-
tuning GLP-1R responses in pancreatic beta cells to control insulin secretion. In the present
study, we demonstrate an important role for the translocation of active GLP-1Rs into liquid-
ordered plasma membrane nanodomains, which act as hotspots for optimal coordination of
intracellular signaling and clathrin-mediated endocytosis. This process is dynamically regu-
lated by agonist binding through palmitoylation of the GLP-1R at its carboxyl-terminal tail.
Biased GLP-1R agonists and small molecule allosteric modulation both influence GLP-1R
palmitoylation, clustering, nanodomain signaling, and internalization. Downstream effects
on insulin secretion from pancreatic beta cells indicate that these processes are relevant to
GLP-1R physiological actions and might be therapeutically targetable.
Introduction
G protein–coupled receptors (GPCRs), the largest membrane receptor family in eukaryotes [1],
are integral membrane proteins, and, as such, both their physical organization and their signal-
ing properties are modulated by the lipid composition of the surrounding membrane [2,3]. The
localization of GPCRs to dynamic membrane nanodomains has been widely reported [4–6].
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These nanodomains, or membrane rafts, which cannot be directly observed in living cells
with current methods [7], are often described as highly organized detergent-resistant, liquid-
ordered, glycosphingolipid- and cholesterol-rich platforms where receptor-signaling complexes
become compartmentalized, facilitating efficient coupling with G proteins [5,8,9]. Additionally,
most GPCRs are modified posttranslationally with one or more palmitic acid chains linked
covalently, but reversibly, via a thioester bond to cysteines within the intracellular domain of
the receptor, in a process known as palmitoylation [2,10]. The insertion of acyl chain(s) is regu-
lated by families of acyltransferases (DHHCs) and palmitoyl protein thioesterases [11,12] and
can be either constitutive or modulated by agonist binding [13,14]. GPCR palmitoylation at or
near the end of its C-terminal tail creates a new membrane anchor and a further intracellular
loop [15] that modifies the GPCR structure and its interactions with specific intracellular part-
ners, favoring receptor partitioning into membrane nanodomains [2,16,17].
Class B GPCRs, such as the glucagon-like peptide-1 receptor (GLP-1R), play crucial roles in
the control of glucose and energy metabolism and are key investigational targets for the treat-
ment of several metabolic disorders including insulin resistance, obesity, and type 2 diabetes
(T2D) [18]. GLP-1 mimetics have been used clinically for over 10 yr [19], but with the current
sharp rise in the worldwide incidence of both T2D and obesity [20], there is a pressing need
to develop more effective drugs with fewer associated side effects. We [21,22] and others [23]
have previously described how GLP-1R signaling responses are modulated by intracellular
membrane trafficking processes, with “biased” agonism [24] being one potentially tractable
means to achieve this in a therapeutic context. In the present study, we focus on the influence
of the lipid microenvironment on GLP-1R trafficking and functionality in pancreatic beta
cells, where it serves to augment glucose-stimulated insulin release to allow tight regulation of
blood glucose [25]. We establish here that binding of GLP-1R to the therapeutic agonist exen-
din-4 (exenatide) triggers increased GLP-1R clustering and reduced lateral diffusion at the
plasma membrane, resulting in the segregation of biologically active GLP-1Rs into cholesterol-
rich plasma membrane nanodomains that enable compartmentalization of acute receptor sig-
naling responses prior to GLP-1R endocytosis via clathrin-coated pits (CCPs). Interestingly,
these processes could be modulated using biased agonists previously derived by us from exen-
din-4 [22], as well as with the small molecule allosteric modulator 4-(3-benzyloxyphenyl)-
2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP) [26,27]. Moreover, we found that
raft localization of the structurally and functionally related glucose-dependent insulinotropic
polypeptide receptor (GIPR), also found in beta cells, was constitutive and not subject to
agonist-mediated regulation. Disruption of the plasma membrane microarchitecture via cho-
lesterol depletion had a substantial impact on acute GLP-1R clustering, signaling, and endocy-
tosis. We also demonstrate that palmitoylation of the GLP-1R, known to occur at cysteine
438 near the C-terminal end of its cytoplasmic tail [28], is an agonist-mediated event that also
plays a role in determining the degree of receptor clustering, nanodomain segregation, and
internalization.
This is, to our knowledge, the first report linking receptor palmitoylation and nanodomain
partitioning to modified or biased responses of a class B GPCR in pancreatic beta cells, open-
ing the door for future studies based on the direct manipulation of these processes to control
GLP-1R action, with the potential to translate into more effective diabetes therapies.
Results
Activated GLP-1Rs accumulate in plasma membrane nanodomains
Association with plasma membrane raft nanodomains is a known mechanism to organize
membrane receptors into signaling microclusters [29]. Localization of GPCRs to membrane
Agonist-induced GLP-1R–nanodomain interactions in beta cells
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rafts can be constitutive or ligand-dependent [30]. To determine the influence of agonist bind-
ing upon GLP-1R raft partitioning in pancreatic beta cells, we measured SNAP-GLP-1R levels
in purified detergent-resistant fractions (DRFs) and detergent-soluble fractions (DSFs) from
total membrane preparations of mouse insulinoma MIN6B1 cells [31] stably expressing
human GLP-1R SNAP-tagged at the extracellular N terminus (MIN6B1 SNAP-GLP-1R cells)
[21]. Stimulation with a saturating concentration of the orthosteric peptide GLP-1R agonist
exendin-4 resulted in increased receptor recruitment to flotillin-positive DRFs compared to
vehicle control conditions, suggesting increased partitioning into membrane nanodomains
(Fig 1A). The increased raft partitioning primarily concerned the poly-glycosylated fraction of
the receptor [32] (S1A Fig), known to represent the receptor pool functional for agonist bind-
ing at the cell surface [33,34] (S1B Fig). Increased enrichment of poly-glycosylated GLP-1Rs in
membrane raft fractions was also present at lower concentrations of exendin-4 and upon stim-
ulation with the endogenous agonist GLP-1(7–36)NH2 (S1C Fig). To corroborate this bio-
chemical finding, we developed a new method to monitor SNAP-GLP-1R localization in
cholesterol-rich nanodomains using time-resolved (TR)-Fo¨rster resonance energy transfer
(FRET) and the solvatochromic membrane probe NR12S [35], as the latter shows blue-shifted
emission in liquid-ordered compared to liquid-disordered membrane environments (S1D
Fig). In cells expressing SNAP-GLP-1R labeled with the long-lived lanthanide FRET donor
Lumi4-Tb, TR-FRET was increased upon exendin-4 addition (S1E Fig), indicating relative
movement between the Lumi4-Tb-labeled GLP-1R extracellular domain and the plasma mem-
brane, possibly reflecting the closure of the receptor extracellular domain upon ligand binding,
as recently suggested [36]. This signal increase was preferentially detected at the blue-shifted,
liquid-ordered–associated part of the spectrum (S1F–S1H Fig), consistent with our earlier
observation that exendin-4 stimulation causes SNAP-GLP-1R translocation into detergent-
resistant membrane nanodomains.
As raft association is known to regulate cell surface receptor clustering [8], we next deter-
mined the degree of GLP-1R clustering at the plasma membrane before and after stimulation
with exendin-4. We performed electron microscopy (EM) analysis of intact 2D sheets of apical
membranes ripped off from adherent MIN6B1 SNAP-GLP-1R cells labeled live with the mem-
brane-impermeable BG-SS-PEG4-biotin SNAP-tag probe followed by gold-conjugated strep-
tavidin (Fig 1B, S1I Fig). Quantification of gold-particle distances to the nearest neighbor
showed increased clustering of SNAP-GLP-1Rs following exendin-4 stimulation. This was
supported by total internal reflection fluorescence (TIRF)-photoactivatable localization
microscopy (PALM) data, which showed an increase in the average number of receptors per
cluster after 1 min of exendin-4 stimulation (Fig 1C), with receptor oligomers already present
in basal conditions in keeping with a previous report [37]. To gain more kinetic information
on agonist-induced GLP-1R clustering, we used a dual surface labeling approach that allows
detection of receptor–receptor interactions by TR-FRET. Because of the long-lived fluores-
cence of Lumi4-Tb, energy transfer in this assay results from both stable and transient pro-
tein–protein interactions, which increases when receptors are in closer proximity [38,39].
Using rat insulinoma INS-1 832/3 cells engineered by clustered regularly interspaced short pal-
indromic repeat (CRISPR)/CRISPR-associated 9 (Cas9) to delete endogenous GLP-1R [40]
stably expressing human SNAP-GLP-1R (INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells), we
detected a rapid increase in TR-FRET with exendin-4, which reached a maximum within 10
min (Fig 1D).
Membrane nanodomains have often been described as hotspots for signaling as a result of
cosegregation of receptors with their corresponding signaling effectors [5]. Using MIN6B1
SNAP-GLP-1R cells expressing the yellow fluorescent protein (YFP)-tagged Gs alpha subunit
(GαS), we found that GαS-YFP clearly partitioned into DRFs both before and after exendin-4
Agonist-induced GLP-1R–nanodomain interactions in beta cells
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Fig 1. Agonist-induced SNAP-GLP-1R clustering and recruitment to membrane nanodomains. (A) SNAP-GLP-1R distribution within TMFs, DRFs, and DSFs
isolated from MIN6B1 cells stably expressing SNAP-GLP-1R treated with vehicle (“Veh”) or 100 nM exendin-4 (“Ex4”) for 2 min, with flotillin as a marker of
membrane raft enrichment. Inset shows quantification of poly-glycosylated SNAP-GLP-1R levels in DRFs; individual results normalized to flotillin (raft loading
control) and expressed in AU, n = 6, paired t test. (B) Electron micrographs of gold-labeled SNAP-GLP-1Rs (arrows) from 2D plasma membrane sheets isolated
from MIN6B1 cells stably expressing SNAP-GLP-1R following SNAP-tag gold labeling and treatment with vehicle or 100 nM exendin-4 for 2 min. An example of a
receptor cluster is shown for the exendin-4-treated condition. Size bars, 100 nm. Mean distances to the nearest neighbor, quantified from a minimum of n = 1,000
gold particles per condition, are shown, unpaired t test. (C) Representative heatmaps of plasma membrane FLAG-GLP-1R localization following TIRF-PALM
imaging and reconstruction with QuickPALM plugin (Fiji) in HEK293 cells stably expressing FLAG-GLP-1Rs labeled with anti-FLAG CAGE 500 antibody prior to
stimulation with vehicle or 100 nM exendin-4 for 2 min. Size bars, 1 μm. Average cluster sizes from n = 11 regions per condition, paired t test. (D) Agonist-induced
SNAP-GLP-1R clustering in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells dual-labeled with Lumi4-Tb and SNAP-Surface 647, treated with vehicle or 100 nM
exendin-4, TR-FRET displayed as fold increase relative to individual baseline, n = 4. (E) GαS-YFP distribution within TMFs, DRFs, and DSFs isolated from MIN6B1
SNAP-GLP-1R cells transiently transfected with GαS-YFP prior to treatment with vehicle or 100 nM exendin-4 for 2 min, with flotillin as a marker of membrane raft
enrichment. (F) Level of β-arrestin-2 (“βarr2”) recruitment to the GLP-1R in DSFs versus DRFs of CHO-PathHunter (DiscoverX) cells expressing ProLink-tagged
human GLP-1R and β-arrestin-2-EA. β-arrestin-2 recruitment was calculated as fold increase of exendin-4 over vehicle condition, normalized to GLP-1R levels in
each membrane fraction, and expressed as the fraction of total β-arrestin-2 recruitment for each experimental repeat, n = 4, paired t test. �p< 0.05, ���p< 0.001, by
statistical test indicated in the text. All data are shown as mean ± SEM. Underlying raw data for all the panels included in this figure can be found in S1 Data, and
uncropped blots from this figure can be found in S1 Raw Images. AU, arbitrary unit; DRF, detergent-resistant fraction; DSF, detergent-soluble fraction; GαS, Gs
alpha subunit; GLP-1R, glucagon-like peptide-1 receptor; HEK293, human embryonic kidney 293; PALM, photoactivatable localization microscopy; TIRF, total
internal reflection fluorescence; TMF, total membrane fraction; TR-FRET, time-resolved Fo¨rster resonance energy transfer; YFP, yellow fluorescent protein.
https://doi.org/10.1371/journal.pbio.3000097.g001
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stimulation (Fig 1E). Moreover, exendin-4-induced recruitment of the active GPCR regulatory
factor β-arrestin-2 [41] to the GLP-1R was significantly increased in DRFs versus DSFs of Chi-
nese hamster ovary (CHO)-PathHunter cells expressing ProLink (PK)-tagged human GLP-1R
and β-arrestin-2-EA (Fig 1F).
Effect of methyl-β-cyclodextrin-induced nanodomain disruption on GLP-
1R behavior
To investigate the effect of nanodomain recruitment on GLP-1R cellular behavior in beta
cells, we used methyl-β-cyclodextrin (MβCD) to disrupt the plasma membrane architecture
via sequestration of cholesterol and other lipids [42]. Efficiency of cholesterol depletion
by MβCD was determined by filipin staining and quantified biochemically; note also that
MβCD treatment did not alter receptor surface SNAP-GLP-1R expression (S2A–S2C Fig). We
observed that binding affinity of the fluorescent exendin-4 conjugate exendin-4-K12-fluores-
cein isothiocyanate (FITC) [22] to SNAP-GLP-1R at equilibrium was reduced by MβCD in a
dose-dependent manner, as measured by TR-FRET [43] (Fig 2A, S2D Fig). Kinetic binding
studies suggested that this was due to faster agonist dissociation (S2E and S2F Fig). Displaying
a similar dependency on the concentration of MβCD used, nanodomain disruption also
reduced maximal exendin-4-induced GLP-1R clustering (Fig 2B and 2C, S2G Fig). MβCD
treatment was also effective in reducing both basal and exendin-4-induced NR12S-linked
increases in TR-FRET from the liquid-ordered-associated portion of the spectrum (S2H Fig),
as expected from its lipid raft-disrupting properties.
Membrane nanodomains have also been implicated in coordination of receptor signaling
and endocytosis [44]. In keeping with this, coupling of endogenously expressed GLP-1R in
wild-type INS-1 832/3 cells to cyclic adenosine monophosphate (cAMP) production was
reduced by MβCD (Fig 2D), with both FRET-based conformational biosensor measurements
of cAMP production using TEpacVV [45] and raft-associated activation of protein kinase A
(PKA) using AKAR4-Lyn [46], showing a similar pattern (S2I Fig). Additionally, confocal
microscopy analysis in beta and nonbeta cells showed a marked inhibition of exendin-
4-induced SNAP-GLP-1R internalization after MβCD treatment (Fig 2E and 2F, S2J and S2K
Fig, S1 and S2 Movies). Using different techniques to monitor uptake of the fluorescent exen-
din-4 ligands exendin-4-K12-FITC and exendin-4-K12-5-carboxytetramethylrhodamine
(TMR) at different MβCD concentrations in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells
again showed a similar MβCD dose relationship to that observed for binding affinity and clus-
tering, albeit with some remaining receptor-mediated agonist uptake detected even at maximal
doses of MβCD (Fig 2G and 2H, S2L and S2M Fig).
Endocytosis of receptors previously recruited to membrane nanodomains can occur via a
range of clathrin-dependent and clathrin-independent pathways, with the specific pathway
utilized in each case being particular to each individual receptor [47–50]. We therefore investi-
gated the route of GLP-1R endocytosis by performing TIRF microscopy analysis of INS-1 832/
3 GLP-1R−/− SNAP-GLP-1R cells expressing a hemagglutinin (HA)-tagged version of the cla-
thrin adaptor protein 2 (AP2) following 1-min stimulation with exendin-4. We found clus-
tered SNAP-GLP-1Rs greatly colocalized with AP2-HA loci at the plasma membrane
(Manders’ coefficient 0.967 ± 0.001) (Fig 2I), indicating that the main pathway of entry for
GLP-1Rs in these cells is clathrin-mediated. To support these results, we performed EM analy-
sis of ultrathin sections of MIN6B1 SNAP-GLP-1R cells gold-labeled as in Fig 1. Stimulation
with exendin-4 for 1 min resulted in the identification of SNAP-GLP-1R-bound gold particles
at different stages of CCP formation (Fig 2J).
Agonist-induced GLP-1R–nanodomain interactions in beta cells
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Fig 2. Inhibition of nanodomain compartmentalization reduces GLP-1R signaling and trafficking responses. (A) Equilibrium
binding affinity measurements for exendin-4 (“Ex4”)-K12-FITC in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells pretreated with
indicated concentration of MβCD, n = 5, one-way randomized block ANOVA with Dunnett’s test versus vehicle. (B) Effect of 45-min
cholesterol depletion with indicated MβCD concentration on SNAP-GLP-1R clustering induced by 100 nM exendin-4 in INS-1 832/3
GLP-1R−/− SNAP-GLP-1R cells, expressed as the difference between AUC for exendin-4 versus vehicle-induced signal over 30 min,
n = 5, 3-parameter logistic fit of pooled data shown. (C) Dose-response curves for exendin-4-induced clustering in INS-1 832/3 GLP-
1R−/− SNAP-GLP-1R cells with or without cholesterol depletion with MβCD (10 mM, 45 min), measured by HTRF and quantified as
AUC for each concentration tested, 4-parameter logistic fit of pooled data shown and used to quantify Emax and log EC50 (vertical
dotted lines), paired t tests performed on parameter estimates from n = 5 experimental repeats. HTRF traces shown in S2H Fig. (D)
cAMP dose response to exendin-4 in wt INS-1 832/3 cells, 10-min stimulation with 500 μM IBMX, normalized to FSK response
(10 μM), 4-parameter logistic fit of pooled data shown and used to quantify Emax and log EC50 (vertical dotted lines), paired t tests
Agonist-induced GLP-1R–nanodomain interactions in beta cells
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Recruitment of β-arrestins to active GPCRs has traditionally been considered as a means of
receptor desensitization coupled to clathrin-dependent endocytosis [41]. In a previous study,
we detected a very transient delay on GLP-1R internalization in cells lacking both β-arrestin-1
and β-arrestin-2, out of keeping with the more marked effects on signaling responses, which
we now attribute primarily to avoidance of β-arrestin-mediated desensitization at the plasma
membrane [22]. In view of our latest observation of the profound effect of cholesterol deple-
tion on GLP-1R internalization, we reassessed the contribution of β-arrestins with and without
MβCD exposure. Using diffusion-enhanced resonance energy transfer (DERET) [51], we first
noted very minor differences in agonist-induced SNAP-GLP-1R endocytosis in wild-type ver-
sus β-arrestin-1/2 knockout human embryonic kidney 293 (HEK293) cells [52] (Fig 3A and
3B). However, endocytosis was substantially inhibited by MβCD irrespective of β-arrestin sta-
tus (Fig 3C), suggesting that preservation of membrane nanodomain organization, rather than
recruitment of β-arrestins, is critical to sustain SNAP-GLP-1R cell entry. Indeed, exendin-
4-induced SNAP-GLP-1R clustering was robust in both cell types (Fig 3D), and we also found
similar binding affinities for exendin-4-K12-FITC (S3A and S3B Fig). In view of the persis-
tence of GLP-1R endocytosis in the absence of β-arrestins, and as these are classically thought
to couple GPCRs to clathrin via AP2 [53], we again probed the route of GLP-1R endocytosis
by TIRF microscopy in wild-type versus β-arrestin-1/2 knockout cells. We found a high degree
of colocalization of clustered SNAP-GLP-1Rs with AP2 loci in both cell types (Manders’ coeffi-
cients 0.969 ± 0.005 and 0.967 ± 0.002, wild-type and β-arrestin-1/2 knockout, respectively)
(Fig 3E). Overall, our results suggest that the main pathway for entry of GLP-1Rs is clathrin-
mediated but does not require β-arrestins.
Role of agonist-mediated palmitoylation in controlling GLP-1R behavior
C-terminal palmitoylation is one of the means by which GPCRs may partition into membrane
rafts [2,16,17]. Prompted by this, and by a previous report demonstrating constitutive palmi-
toylation of the GLP-1R cytoplasmic tail at cysteine 438 [28], we analyzed the importance of
this posttranslational modification in GLP-1R agonist-dependent nanodomain segregation.
Using CHO SNAP-GLP-1R cells, we detected a low level of basal GLP-1R palmitoylation
that was noticeably increased following exendin-4 stimulation (Fig 4A). To confirm these
results in pancreatic beta cells, we repeated the palmitoylation assay in INS-1 832/3 GLP-1R−/−
SNAP-GLP-1R cells, where we detected increased GLP-1R palmitoylation following stimula-
tion with a range of exendin-4 concentrations, as well as with the endogenous agonist GLP-1
performed on parameter estimates from n = 5 experimental repeats. (E) Confocal analysis of SNAP-GLP-1R internalization in MIN6B1
SNAP-GLP-1R cells labeled with SNAP-Surface 549 probe (red) for 30 min and then incubated with or without MβCD (10 mM, 1 h)
before stimulation with 100 nM exendin-4 for 15 min. Nuclei (DAPI), blue; size bars, 10 μm. (F) As in (E) but with INS-1 832/3 GLP-
1R−/− SNAP-GLP-1R cells. (G) Effect of indicated concentration of MβCD on uptake of exendin-4-K12-FITC in INS-1 832/3 GLP-
1R−/− SNAP-GLP-1R cells, expressed as AUC relative to baseline for each concentration, n = 5, 3-parameter logistic fit of pooled data
shown. (H) Level of exendin-4-K12-TMR uptake in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells, calculated as AUC of time-lapse
confocal microscopy kinetic traces (shown in S2M Fig) after pretreatment with the indicated MβCD concentration for 1 h, one-way
ANOVA with Dunnett’s test, n = 6 traces analyzed from three time-lapse acquisitions per condition. (I) TIRF plasma membrane
microscopy analysis of INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells transiently transfected with μ2-HA-WT, which codes for the μ2
domain of the clathrin adaptor AP2 fused to an HA tag (AP2-HA, red), labeled with SNAP-Surface 488 (green) and stimulated for 1
min with 100 nM exendin-4 prior to fixation and HA-tag immunofluorescence; size bar, 10 μm. (J) Representative electron micrographs
depicting different stages of CCP endocytosis of gold-labeled SNAP-GLP-1Rs (red arrows) in MIN6B1 SNAP-GLP-1R cells stimulated
for 1 min with 100 nM exendin-4; size bars, 100 nm. �p< 0.05, ���p< 0.001, “ns” indicates nonsignificant, by statistical test indicated in
the text. All data are shown as mean ± SEM, with individual replicates indicated where relevant. Underlying raw data for all the panels
included in this figure can be found in S1 Data, and a dose-response summary for this figure is included in S1 Table. AP2, adaptor
protein 2; AUC, area under the curve; cAMP, cyclic adenosine monophosphate; CCP, clathrin-coated pit; FITC, fluorescein
isothiocyanate; FSK, forskolin; GLP-1R, glucagon-like peptide-1 receptor; HA, hemagglutinin; HTRF, homogenous time-resolved
fluorescence; IBMX, isobutylmethylxanthine; MβCD, methyl-β-cyclodextrin; TIRF, total internal reflection fluorescence; wt, wild type.
https://doi.org/10.1371/journal.pbio.3000097.g002
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(7–36)NH2 (Fig 4B). GLP-1R palmitoylation was also examined in MIN6B1 SNAP-GLP-1R
cells following exendin-4 stimulation in the presence or absence of the palmitoylation inhibitor
2-bromopalmitate (2-BP) (Fig 4C) and following incubation with excess palmitate (Fig 4D),
where it was greatly enhanced.
In order to further analyze the specific role of GLP-1R palmitoylation on exendin-4-trig-
gered cellular effects, we mutated SNAP-GLP-1R to replace cysteine 438, previously described
as its only palmitoylation site [28], with alanine (C438A; Fig 5A). We first confirmed that
mutant SNAP-GLP-1R C438A is no longer palmitoylated following exendin-4 stimulation
Fig 3. β-arrestins are dispensable for GLP-1R clustering and endocytosis. (A) SNAP-GLP-1R internalization measured by DERET in wt and β-arrestin-less
(“KO”) HEK293 cells stably expressing SNAP-GLP-1R, treated with 100 nM exendin-4 or vehicle (“Veh”), expressed relative to baseline, n = 4. Inset shows AUC,
paired t test. (B) Dose responses for SNAP-GLP-1R internalization measured by DERET, analogous experiments to (A), quantified as AUC for each dose tested,
4-parameter logistic fit of pooled data shown, n = 4. (C) Confocal analysis of SNAP-GLP-1R internalization in wt and β-arrestin-less HEK293 cells stably expressing
SNAP-GLP-1R, labeled with SNAP-Surface 549 (red) and treated with or without MβCD before stimulation with 100 nM exendin-4 for 15 min. Nuclei (DAPI), blue;
size bars, 10 μm. (D) SNAP-GLP-1R clustering measured by HTRF in wt and β-arrestin-less HEK293 cells stably expressing SNAP-GLP-1R, treated with 100 nM
exendin-4 or vehicle, expressed relative to baseline, n = 4. Inset shows AUC, paired t test. (E) TIRF microscopy analysis of plasma membranes from wt and β-
arrestin-less HEK293 cells stably expressing SNAP-GLP-1R and transiently transfected with AP2-HA, labeled with SNAP-Surface 488 (green) and stimulated for 1
min with 100 nM exendin-4 prior to fixation and HA-tag immunofluorescence (red); size bars, 10 μm, “ns” indicates nonsignificant, by statistical test indicated in the
text. All data are shown as mean ± SEM. Underlying raw data for all the panels included in this figure can be found in S1 Data, and a dose-response summary for this
figure is included in S2 Table. AP2, adaptor protein 2; AUC, area under the curve; DERET, diffusion-enhanced resonance energy transfer; GLP-1R, glucagon-like
peptide-1 receptor; HA, hemagglutinin; HEK293, human embryonic kidney 293; HTRF, homogenous time-resolved fluorescence; MβCD, methyl-β-cyclodextrin;
TIRF, total internal reflection fluorescence; wt, wild type.
https://doi.org/10.1371/journal.pbio.3000097.g003
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(Fig 5B). Surface levels of both wild-type and C438A SNAP-GLP-1Rs were similar when
expressed stably or transiently (S4A and S4B Fig), suggesting that constitutive palmitoylation
is not required for efficient delivery of the GLP-1R to the plasma membrane, unlike for some
other GPCRs [54]. Additionally, we did not detect any significant differences in binding affin-
ity of exendin-4-K12-FITC to mutant versus wild-type GLP-1R (Fig 5C, S4C and S4D Fig).
In keeping with a putative role for palmitoylation in the formation of receptor clusters, we
observed delayed exendin-4-triggered clustering with C438A SNAP-GLP-1R compared to
wild type, albeit with a full response eventually appearing after longer agonist exposure (Fig
5D, kinetic traces shown in S4E Fig). Moreover, EM analysis of nearest neighbors in 2D
plasma membrane sheets showed reduced exendin-4-induced clustering with the C438A
mutant (Fig 5E). Recruitment of poly-glycosylated C438A SNAP-GLP-1Rs to DRFs after exen-
din-4 stimulation was concomitantly reduced with C438A compared to wild-type receptor
(fold increase versus wild type of 0.57 ± 0.02) (Fig 5F).
We next compared the trafficking properties of wild-type versus C438A mutant SNAP-
GLP-1R stably expressed in INS-1 832/3 GLP-1R−/−, as well as in MIN6B1 cells in which
endogenous GLP-1R was knocked out by CRISPR/Cas9 (S4F Fig). We detected reduced inter-
nalization of the C438A mutant in both beta cell lines (Fig 5G, S4G Fig), with no effect on
receptor recycling after internalization (S4H and S4I Fig). Internalization measurements by
DERET or time-lapse confocal microscopy of wild-type or C438A SNAP-GLP-1Rs in INS-1
Fig 4. GLP-1R undergoes agonist-induced palmitoylation. (A) Total input (“I”) and palmitoylated (“P”) SNAP-GLP-1R fractions from CHO SNAP-GLP-1R cells
treated with vehicle (“Veh”) or 100 nM exendin-4 (“Ex4”) for 10 min. (B) Total input and palmitoylated SNAP-GLP-1R fractions from INS-1 832/3 GLP-1R−/−
SNAP-GLP-1R cells treated with vehicle or the indicated concentrations of exendin-4 or GLP-1 for 10 min. (C) Total input and palmitoylated SNAP-GLP-1R fractions
from MIN6B1 SNAP-GLP-1R cells treated with 100 nM exendin-4 for 10 min, with and without pretreatment with 200 μM 2-BP overnight. (D) Total input and
palmitoylated SNAP-GLP-1R fractions from MIN6B1 SNAP-GLP-1R cells treated with 200 μM palmitate/BSA overnight. Uncropped blots from this figure can be
found in S1 Raw Images. 2-BP, 2-bromopalmitate; BSA, bovine serum albumin; CHO, Chinese hamster ovary; GLP-1R, glucagon-like peptide-1 receptor.
https://doi.org/10.1371/journal.pbio.3000097.g004
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Fig 5. Reduced nanodomain segregation, signaling, and internalization of the palmitoylation-deficient GLP-1R
C438A mutant. (A) Cartoon showing C-terminal cysteine residues in the GLP-1R cytoplasmic tail, with C438
highlighted as the putative palmitoylation site. (B) Analysis of SNAP-GLP-1R palmitoylation levels in CHO
SNAP-GLP-1R wt or C438A cells treated with 100 nM exendin-4 for 10 min. (C) Equilibrium dissociation binding
constant of exendin-4-K12-FITC determined from HTRF kinetic binding experiments in INS-1 832/3 GLP-1R−/−
stably expressing wt or C438A SNAP-GLP-1R, n = 4, paired t test. Binding traces shown in S4C Fig. (D) Dose
responses for exendin-4-induced clustering, measured by HTRF in INS-1 832/3 GLP-1R−/− stably expressing wt or
C438A SNAP-GLP-1R, expressed as AUC for each concentration tested after segmentation into indicated time
windows, 4-parameter logistic fits of pooled data shown with Emax and log EC50 (vertical dotted lines), paired t tests
comparing parameter estimates for n = 5 repeats. Traces shown in S4E Fig. (E) Representative electron micrographs of
gold-labeled SNAP-GLP-1Rs (arrows) from 2D plasma membrane sheets isolated from HEK293 cells stably expressing
wt or C438A mutant SNAP-GLP-1R following SNAP-tag gold labeling and treatment with 100 nM exendin-4 for 2
min; size bars, 100 nm. Average distance to the nearest neighbor is shown from a minimum of n = 300 gold particles
per condition, unpaired t test. (F) SNAP-GLP-1R wt versus C438A distribution within TMFs, DRFs, and DSFs isolated
from INS-1 832/3 GLP-1R−/− cells stably expressing each type of SNAP-GLP-1R and treated with 100 nM exendin-4
for 2 min, with flotillin as a marker of membrane raft enrichment. (G) Confocal analysis of SNAP-GLP-1R wt versus
C438A internalization in INS-1 832/3 GLP-1R−/− cells stably expressing each type of SNAP-GLP-1R following labeling
with SNAP-Surface 488 for 30 min and stimulation with 100 nM exendin-4 for 15 min. Nuclei (DAPI), blue; size bars,
10 μm. (H) Dose responses for wt or C438A SNAP-GLP-1R internalization induced by exendin-4 in INS-1 832/3 GLP-
1R−/− cells stably expressing each SNAP-receptor type, measured by DERET, quantified as AUC for each
concentration tested, 4-parameter logistic fits of pooled data shown with Emax and log EC50 (vertical dotted lines),
paired t tests performed on parameter estimates from n = 5 repeats. (I) Dynamic internalization profile, assessed as
decrease in plasma membrane signal, from time-lapse confocal microscopy data of INS-1 832/3 GLP-1R−/− cells stably
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832/3 GLP-1R−/− cells again revealed reduced internalization with the palmitoylation-deficient
mutant (Fig 5H and 5I, S4J Fig, S3 and S4 Movies).
The GLP-1R C438A mutation has variously been reported to result in reduced cAMP sig-
naling [28,55] or to have no effect [56], when measured in HEK293 or CHO-K1 cells. In accor-
dance with the former reports, we found that cAMP production was reduced with C438A
compared to wild-type SNAP-GLP-1R in INS-1 832/3 GLP-1R−/− cells (Fig 5J). Consistent
with this finding, exendin-4-induced recruitment of β-arrestin-2 to C438A SNAP-GLP-1Rs
was reduced compared to wild type (Fig 5K). Critically, this translated into significant reduc-
tions in exendin-4-induced insulin secretion (Fig 5L), indicating that GLP-1R palmitoylation
may play an important role in glucose homeostasis or responses to pharmacological GLP-1R
agonists in diabetes.
The closely related GIPR is also found in beta cells and plays a similar role to GLP-1R in
regulating glucose-stimulated insulin release [25]. Interestingly, GIPR C-terminal cysteine
residues 406 and 411 have previously been implicated in GIPR desensitization, although pal-
mitoylation was not examined [57]. Highlighting that agonist-dependent modulation of pal-
mitoylation and recruitment to membrane nanodomains are receptor-specific responses, we
found that GIPR displayed a high degree of constitutive palmitoylation, which was not further
increased by GIP stimulation (S5A Fig). Similarly, SNAP-GIPR was extensively recruited to
DRFs under basal conditions (S5B Fig) and showed a higher degree of constitutive clustering
compared to GLP-1Rs, despite similar surface expression levels, with no detectable increase
upon GIP addition (S5C Fig). Although not agonist-regulated, GIPR localization to choles-
terol-rich nanodomains was functionally important, as its endocytosis was virtually abolished
after MβCD treatment (S5D Fig).
Biased GLP-1R agonists show distinct patterns of clustering and
palmitoylation
We have previously investigated the effects of a panel of exendin-4-derived biased GLP-1R
agonists with marked differences in binding kinetics, preference for cAMP versus β-arrestin
recruitment, and receptor internalization and recycling [22]. Although they were measured
acutely, bias profiles were predictive of the ability of each agonist to support long-term GLP-
1R signaling and insulin secretion from beta cells, with lower-affinity, slow-internalizing
agonists more efficacious for longer-term responses despite being less potent acutely. Given
that differential palmitoylation and/or nanodomain partitioning has been linked to the
expressing wt or C438A SNAP-GLP-1R following labeling with SNAP-Surface 549 for 30 min and stimulation with
100 nM exendin-4, n = 4, data normalized to baseline for every individual trace. Inset shows AUC calculated from
main graph, unpaired t test. (J) Exendin-4-induced cAMP in INS-1 832/3 GLP-1R−/− cells stably expressing wt or
C438A SNAP-GLP-1R, 10-min exendin-4 stimulation with 500 μM IBMX, n = 6, 3-parameter fits shown and used to
quantify Emax and log EC50 (vertical dotted lines), paired t tests. (K) Dose-response curves of β-arrestin-2 recruitment
to the GLP-1R in HEK293 β-arrestin-2-EA cells transiently transfected with wt or C438A SNAP-GLP-1R-PK,
normalized to basal response, n = 5, Emax compared by paired t test. (L) Exendin-4-induced insulin secretion in INS-1
832/3 GLP-1R−/− cells stably expressing wt or C438A SNAP-GLP-1R, 16-h stimulation at 11 mM glucose, expressed
relative to 11 mM glucose alone, 3-parameter fits of pooled data shown, Emax from n = 4 repeats compared by paired t
test. �p< 0.05, ��p< 0.01, ����p< 0.0001, “ns” indicates nonsignificant, by statistical test indicated in the text. All data
are shown as mean ± SEM, with individual replicates indicated where relevant. Underlying raw data for all the panels
included in this figure can be found in S1 Data, and a dose-response summary for this figure is included in S3 Table;
uncropped blots from this figure can be found in S1 Raw Images. AUC, area under the curve; cAMP, cyclic adenosine
monophosphate; cBF, cleaved bound fraction (corresponding to the palmitoylated pool); CHO, Chinese hamster
ovary; cUF, cleaved unbound fraction; DERET, diffusion-enhanced resonance energy transfer; DRF, detergent-
resistant fraction; DSF, detergent-soluble fraction; FITC, fluorescein isothiocyanate; GLP-1R, glucagon-like peptide-1
receptor; HEK293, human embryonic kidney 293; HTRF, homogenous time-resolved fluorescence; IF, input fraction;
pBF, preserved bound fraction; pUF, preserved unbound fraction; TMF, total membrane fraction; wt, wild type.
https://doi.org/10.1371/journal.pbio.3000097.g005
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Fig 6. GLP-1R palmitoylation, nanodomain clustering, and spatial control of signaling with biased agonists. (A) Total input (“I”)
and palmitoylated (“P”) SNAP-GLP-1R fractions from CHO-K1 cells stably expressing SNAP-GLP-1R wild type or C438A and treated
with vehicle (“Veh”) or 100 nM of exendin-4 (“Ex4”), exendin-phe1 (“Ex-phe1”), or exendin-asp3 (“Ex-asp3”) for 10 min. (B)
SNAP-GLP-1R distribution within TMFs, DRFs, and DSFs isolated from MIN6B1 SNAP-GLP-1R cells treated with vehicle or indicated
agonist (100 nM) for 2 min, with TfR as a marker of membrane non-raft and flotillin as a marker of membrane raft enrichment. Inset
shows quantification of poly-glycosylated SNAP-GLP-1R levels in DRFs, with individual results normalized to flotillin (raft loading
Agonist-induced GLP-1R–nanodomain interactions in beta cells
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establishment of signal bias [58], we explored the possibility that two exemplar agonists from
this panel with opposite bias effects, namely exendin-phe1 and exendin-asp3, might influence
GLP-1R palmitoylation, clustering, and/or recruitment to membrane nanodomains compared
to the parental agonist exendin-4.
We first analyzed the level of SNAP-GLP-1R palmitoylation elicited by these three agonists
and found that stimulation with exendin-asp3, a high-affinity agonist biased toward β-arrestin
recruitment and internalization, increased SNAP-GLP-1R palmitoylation compared to exen-
din-4, whereas stimulation with exendin-phe1, a low-affinity agonist biased in opposite direc-
tions, had a reduced effect (Fig 6A). We next examined whether a similar pattern was present
for membrane raft partitioning and found that a smaller proportion of poly-glycosylated
SNAP-GLP-1Rs segregated to DRFs following stimulation with exendin-phe1, with exendin-
asp3 triggering a similar level of raft recruitment to exendin-4 (Fig 6B). Supporting this find-
ing, NR12S FRET measurements indicated a greater increase in signal from liquid-ordered
versus liquid-disordered spectral regions with exendin-4 and exendin-asp3 in comparison to
exendin-phe1 (S6A and S6B Fig). In keeping with this, both SNAP-GLP-1R clustering and
internalization were virtually absent with exendin-phe1 compared to either exendin-4 or exen-
din-asp3 (Fig 6C, S6C–S6E Fig).
In order to further characterize the behavior of individual GLP-1Rs at the plasma mem-
brane following stimulation with these agonists, we performed single-molecule TIRF micros-
copy tracking experiments to identify individual receptor trajectories [59,60] in CHO-K1 cells
transiently expressing SNAP-GLP-1R at low/physiological levels (Fig 6D, S5–S8 Movies). A
mean squared displacement (MSD) analysis was used to analyze individual GLP-1R trajecto-
ries [60,61]. These were classified into four groups (S6F Fig) based on both their diffusion coef-
ficient (Fig 6E, top) and their anomalous diffusion exponent (Fig 6E, bottom). Under vehicle
conditions, 14% of the receptors were immobile, 32% were confined (subdiffusion), 48% fol-
lowed normal Brownian diffusion, and 6% had directional motion (superdiffusion). Following
exendin-4 stimulation, the fraction of immobile receptors increased to 77%. Exendin-asp3
caused very similar changes to exendin-4 (64% of immobile receptors). Conversely, the effect
of exendin-phe1 stimulation was very similar to that of vehicle, with only 12% of the receptors
immobile and no significant changes upon the distribution of mobile receptors among the
control), n = 3, one-way repeat-measures ANOVA with Dunnett’s test versus exendin-4. (C) Dose responses showing SNAP-GLP-1R
clustering induced by each agonist in INS-1 GLP-1R−/− SNAP-GLP-1R cells, expressed as AUC for each concentration tested,
4-parameter logistic fits of pooled data shown with Emax and log EC50 (vertical dotted lines), one-way repeat-measures ANOVA with
Tukey’s test comparing parameter estimates from n = 5 repeats. Traces shown in S6E Fig. (D) Representative snapshots of single-
molecule TIRF image sequences acquired from plasma membranes of CHO-K1 cells transiently expressing SNAP-GLP-1R labeled with
SNAP-Surface 549 prior to stimulation with vehicle or 100 nM of the indicated agonist, including overlaid individual trajectories (red).
Size bars, 5 μm, and 2 μm for insets. (E, top) Frequency of immobile versus mobile single-molecule SNAP-GLP-1R trajectories
following the indicated treatment, based on the generalized diffusion coefficient D. (E, bottom) Frequency of subdiffusion, normal
diffusion, and superdiffusion of single-molecule SNAP-GLP-1Rs following the indicated treatment, based on the anomalous diffusion
exponent α. Trajectories (6,100–11,000 for each group) analyzed with u-track (MATLAB) and further categorized using custom
algorithms (see Materials and methods section). (F) Summary of relative potency changes in CHO SNAP-GLP-1R cells treated with the
indicated agonist measured using the FRET biosensors TEpacVV, AKAR4-NES, and AKAR4-Lyn. Bias was determined using the relative
potency ratio approach by first subtracting log EC50 values for exendin-phe1 and exendin-asp3 from that of exendin-4 and then
normalizing values for AKAR4-Lyn from those of AKAR4-NES or TEpacVV generated in the same experiment for each agonist, n = 5,
two-way repeat-measures ANOVA with Sidak’s test comparing exendin-phe1 with exendin-asp3. For further details, see Materials and
methods. Traces are shown in S7A and S7B Fig. �p< 0.05 by statistical test indicated in the text. All data are shown as mean ± SEM.
Underlying raw data for all the panels included in this figure can be found in S1 Data, and a dose-response summary for this figure is
included in S4 Table; raw trajectory coordinates and MSDs used to calculate generalized diffusion coefficient D and anomalous
diffusion exponent α in (E) can be downloaded from https://doi.org/10.6084/m9.figshare.c.4592000; uncropped blots from this figure
can be found in S1 Raw Images. AUC, area under the curve; CHO, Chinese hamster ovary; DRF, detergent-resistant fraction; DSF,
detergent-soluble fraction; FRET, Fo¨rster resonance energy transfer; GLP-1R, glucagon-like peptide-1 receptor; MSD, mean squared
displacement; TfR, transferrin receptor; TIRF, total internal reflection fluorescence; TMF, total membrane fraction.
https://doi.org/10.1371/journal.pbio.3000097.g006
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different groups, indicating that stimulation with this biased agonist is associated with a differ-
ent pattern of lateral diffusion of plasma membrane GLP-1Rs.
Next, we determined signaling responses to each biased agonist at multiple doses in real
time in CHO SNAP-GLP-1R cells with TEpacVV, AKAR4-NES (cytosolic PKA sensor) or
AKAR4-Lyn biosensors (S7A Fig), allowing the construction of sequential dose-response
curves across the entire stimulation period to observe changes in potency over time (S7B Fig),
so as to assess whether the differential membrane raft translocation of GLP-1R by biased ago-
nists controls spatial organization of cAMP signaling. These results suggested selective reduc-
tions in nanodomain-specific AKAR4-Lyn signaling with exendin-phe1 compared to exendin-
asp3 (Fig 6F), in keeping with the reduced tendency of this agonist to induce GLP-1R raft
localization. Although the signal bias profiles broadly matched the measured localization pat-
tern for each agonist from membrane fractionation experiments, agreement was not perfect.
In particular, exendin-asp3 displayed enhanced potency for AKAR4-Lyn signaling, despite no
evidence of additional nanodomain translocation beyond that achieved by exendin-4. Never-
theless, these data support the hypothesis that, in contrast with exendin-4, exendin-phe1 fails
to immobilize GLP-1Rs in cholesterol-rich signaling hotspots.
Our earlier observation that treatment with MβCD reduces binding affinity of exendin-
4-K12-FITC (Fig 2) prompted us to question whether agonist-induced GLP-1R clustering
might increase the tendency for dissociating agonist molecules to rebind to nearby receptors,
contributing to affinity measures [62]. In view of the profound differences in agonist-
induced SNAP-GLP-1R clustering with exendin-phe1 versus exendin-4, we compared the
affinity-modulating effects of MβCD on exendin-4-K12-FITC and exendin-phe1-K12-FITC
in parallel (S7C and S7D Fig) and found that MβCD reduced binding affinity of both ligands
to a similar extent. These data suggest that the effect of MβCD on binding kinetics either pre-
cedes or is independent of its effect on receptor clustering, as exendin-phe1-driven clustering
is minimal. Of note, a number of GPCRs have been found to form direct and functional allo-
steric interactions with cholesterol [63,64], the selective depletion of which could underlie
the observed reduction in affinity independently of wider effects on plasma membrane
microarchitecture.
Allosterical control of GLP-1R nanodomain segregation
Previous reports highlight that the GLP-1R-specific positive allosteric modulator (PAM)
BETP [55] can markedly augment responses to weak GLP-1R agonists such as oxyntomodu-
lin [65] and GLP-1(9–36)NH2 [26]. We therefore determined whether BETP played any role
in GLP-1R clustering and nanodomain segregation in beta cells. Indeed, whereas the effect
of BETP or exendin-phe1 alone on clustering in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells
was marginal, coapplication of exendin-phe1 with BETP resulted in rapid SNAP-GLP-1R
clustering, comparable to that obtained with exendin-4 (Fig 7A). These results were sup-
ported by EM analysis from MIN6B1 SNAP-GLP-1R cells stimulated with exendin-phe1 in
the presence or absence of BETP (Fig 7B). We also found that BETP was able to rescue the
reduced SNAP-GLP-1R segregation to membrane nanodomains elicited by exendin-phe1,
with SNAP-GLP-1Rs now being recruited to membrane rafts to the same extent as with
exendin-4 (Fig 7C).
Revisiting the concept of receptor cluster-driven rebinding as a possible contributor to
agonist binding affinity, we found that costimulation with BETP was able to significantly
increase the binding affinity of exendin-phe1-K12-FITC, with a less marked effect on exendin-
4-K12-FITC (Fig 7D, S8A and S8B Fig). This agonist specificity correlates with agonist-specific
BETP effects on GLP-1R clustering and the putative rebinding mechanism consequent to
Agonist-induced GLP-1R–nanodomain interactions in beta cells
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000097 August 20, 2019 14 / 40
Fig 7. Allosteric control of GLP-1R nanodomain segregation, signaling, and trafficking. (A) SNAP-GLP-1R clustering measured by HTRF in
INS-1 GLP-1R−/− SNAP-GLP-1R cells treated with 100 nM exendin-4 (“Ex4”), exendin-phe1 (“Ex-phe1”), or vehicle, ± BETP (10 μM), expressed
relative to baseline, n = 5. Inset shows AUC for each condition, two-way repeat-measures ANOVA with Sidak’s test comparing each
condition ± BETP. (B) Representative electron micrographs of gold-labeled SNAP-GLP-1Rs from 2D plasma membrane sheets isolated from
MIN6B1 SNAP-GLP-1R cells following gold labeling of SNAP-tagged receptors and treatment with 100 nM exendin-phe1 with and without
BETP (10 μM) for 2 min. Average distance to the nearest neighbor quantified from a minimum of n = 155 (− BETP) or n = 330 (+ BETP) gold
Agonist-induced GLP-1R–nanodomain interactions in beta cells
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this, contrasting with the abovementioned agonist-equal affinity changes triggered by MβCD
(S7 Fig).
To determine the functional impact of these changes in beta cells, we analyzed the signaling
and trafficking characteristics of exendin-phe1 in the presence and absence of BETP. Potency
estimates for exendin-phe1-induced cAMP production in INS-1 832/3 cells with endogenous
GLP-1R expression were markedly increased, with a smaller effect on potency when exendin-4
was used as the orthosteric probe (Fig 7E). β-arrestin-2 recruitment to the GLP-1R was also
substantially increased (S8C Fig). Moreover, DERET measurements showed that SNAP-GLP-
1R endocytosis was significantly increased for exendin-phe1 when coapplied with BETP com-
pared to exendin-phe1 alone, with no effect of BETP on vehicle or exendin-4-triggered GLP-
1R internalization (Fig 7F). This was supported by confocal microscopy analysis using FITC
conjugates of exendin-phe1 ± BETP versus exendin-4 (Fig 7G).
To further elucidate the mechanism by which BETP potentiates GLP-1R responses, we
examined the relative contributions of GLP-1R palmitoylation, β-arrestins, and cholesterol-
dependent membrane compartmentalization to its effect. BETP is known to cross the plasma
membrane to covalently bind two intracellular GLP-1R cysteine residues (347 and 438, see Fig
8A for a schematic of BETP GLP-1R binding sites) [55]. Accordingly, BETP caused a signifi-
cant reduction in exendin-4-induced palmitoylation (Fig 8B), indicating that it is able to block
transfer of palmitate to the GLP-1R by binding to its known palmitoylation site. We speculated
that some effects of this allosteric modulator might relate to alterations in receptor conforma-
tion through chemical modification of cysteine 438, in a manner analogous to the effect of pal-
mitoylation at this residue. However, we found that the effect of BETP on internalization of
the C438A SNAP-GLP-1R mutant stimulated by exendin-phe1 was comparable to that of
wild-type receptors (Fig 8C and 8D). This is in keeping with the current understanding that
the pharmacology of BETP is mediated via binding to cysteine 347 rather than 438 [55] and
suggests that, despite its contribution to optimal internalization, cysteine 438 palmitoylation is
not an obligatory event for GLP-1R endocytosis.
As with exendin-4, β-arrestins appear dispensable for exendin-phe1-induced GLP-1R
endocytosis when potentiated by BETP, as shown using the HEK293 β-arrestin-1/2 CRISPR
knockout model (Fig 8E). However, BETP-induced internalization of exendin-phe1-stimu-
lated SNAP-GLP-1R still relies on cholesterol, as pretreatment with MβCD inhibited this pro-
cess to the same extent as for exendin-4 (Fig 8F). Furthermore, TIRF microscopy analysis
particles per condition, unpaired t test. (C) SNAP-GLP-1R distribution within TMFs, DRFs, and DSFs isolated from MIN6B1 SNAP-GLP-1R
cells treated with vehicle or 100 nM of the indicated agonist with or without BETP (10 μM) for 2 min, with flotillin as a marker of membrane raft
enrichment. Inset shows quantification of poly-glycosylated SNAP-GLP-1R levels in DRFs with individual results normalized to flotillin (raft
loading control) shown as vehicle fold increase, n = 3, one-way repeat-measures ANOVA with Dunnett’s test versus exendin-4. (D) Effect of
BETP (10 μM) on equilibrium dissociation binding constants of exendin-4-K12-FITC and exendin-phe1-K12-FITC in INS-1 GLP-1R−/−
SNAP-GLP-1R cells, n = 5, two-way repeat-measures ANOVA with Sidak’s test comparing ± BETP. (E) cAMP responses in INS-1 832/3 cells
with endogenous GLP-1R expression, stimulated for 10 min in presence of 500 μM IBMX with exendin-4 or exendin-phe1 ± BETP (10 μM),
normalized to FSK response (10 μM), 4-parameter logistic fits of pooled data shown with log EC50 (vertical dotted lines), two-way repeat-
measures ANOVA with Sidak’s test comparing ± BETP from n = 5. (F) SNAP-GLP-1R internalization measured by DERET in INS-1 GLP-1R−/−
SNAP-GLP-1R cells treated with 100 nM exendin-4, exendin-phe1, or vehicle ± BETP (10 μM), expressed relative to baseline, n = 5. Inset shows
AUC, two-way repeat-measures ANOVA with Sidak’s test comparing each condition ± BETP. (G) Confocal analysis of the indicated FITC
agonist (green) and SNAP-GLP-1R (red) localization in MIN6B1 SNAP-GLP-1R cells following labeling with SNAP-Surface 549 and stimulation
with 100 nM of the indicated FITC agonist with or without BETP (10 μM) for 10 min or with BETP alone. Nuclei (DAPI), blue; size bars, 10 μm.
�p< 0.05, ��p< 0.01, ���p< 0.001, “ns” indicates nonsignificant, by statistical test indicated in the text. All data are shown as mean ± SEM, with
individual replicates indicated where relevant. Underlying raw data for all the panels included in this figure can be found in S1 Data, and a dose-
response summary for this figure is included in S5 Table; uncropped blots from this figure can be found in S1 Raw Images. AUC, area under the
curve; BETP, 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; cAMP, cyclic adenosine monophosphate; DRF, detergent-
resistant fraction; DSF, detergent-soluble fraction; FITC, fluorescein isothiocyanate; FSK, forskolin; GLP-1R, glucagon-like peptide-1 receptor;
HTRF, homogenous time-resolved fluorescence; IBMX, isobutylmethylxanthine; TMF, total membrane fraction.
https://doi.org/10.1371/journal.pbio.3000097.g007
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Fig 8. Mechanism of BETP-mediated GLP-1R endocytosis. (A) Cartoon depicting sites of covalent modification of GLP-1R by BETP at C347
and C438, as per [55]. (B) Total input (“I”) and palmitoylated (“P”) SNAP-GLP-1R fractions from CHO SNAP-GLP-1R cells treated with 100
nM exendin-4 (“Ex4”) for 10 min in the presence or absence of 10 μM BETP. (C) Confocal analysis of SNAP-GLP-1R C438A (green)
localization in HEK293 cells following labeling with SNAP-Surface 488 and stimulation with exendin-phe1 (“Ex-phe1”) with or without BETP
(10 μM) for 10 min. Nuclei (DAPI), blue; size bars, 10 μm. (D) SNAP-GLP-1R internalization measured by DERET in HEK293 cells transiently
expressing wt or C438A mutant SNAP-GLP-1R, treated with 100 nM exendin-phe1, 10 μM BETP, or both, expressed as fold increase from
baseline, n = 6. (E) Confocal analysis of exendin-phe1-K12-FITC (green) and SNAP-GLP-1R (red) internalization in HEK293 β-arrestin-less
(“βarr1/2 KO”) cells stably expressing SNAP-GLP-1R following labeling with SNAP-Surface 549 and stimulation with 100 nM of exendin-
phe1-K12-FITC for 40 min with or without BETP (10 μM). Nuclei (DAPI), blue; size bars, 10 μm. (F) Confocal analysis of the indicated FITC
agonist (green) and SNAP-GLP-1R (red) localization in MIN6B1 SNAP-GLP-1R cells following labeling with SNAP-Surface 549 and
stimulation with 100 nM of the indicated FITC agonist with or without BETP (10 μM) for 10 min in the presence or absence of MβCD (10 mM,
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suggested that this internalization also proceeds via a clathrin-dependent pathway, as it
involved engagement of AP2 (Fig 8G) and resulted in localization of gold-labeled SNAP-GLP-
1Rs to CCPs (Fig 8H). Overall, these data suggest that BETP favors the same endocytic route as
that followed by GLP-1Rs after orthosteric agonist stimulation.
Discussion
The role of the plasma membrane lipid environment in the control of GPCR functional selec-
tivity remains a relatively underexplored area, primarily because of the technical challenges
associated with the study of lipid–protein cross talk [7]. Despite this, emerging evidence using
newly developed methods places lipid nanodomains as key regulators of GPCR signaling
[2,5,63,66,67].
In the present study, we have unveiled a central role for this lipid context in the modulation
of the biological action of the beta cell GLP-1R, a class B GPCR with a significant role in meta-
bolic regulation and a prime T2D target [25]. We found that GLP-1R clustering within beta
cell membrane nanodomains and receptor palmitoylation at its C-terminal end are agonist-
regulated processes, indicating that the GLP-1R interaction with its surrounding lipid environ-
ment is conditioned by its activation state. These processes are likely to be interconnected.
Agonist-induced changes to GPCR conformation, typically involving outward movement of
transmembrane (TM) helix 6, may result in energetically unfavorable “hydrophobic mis-
match” between the exterior receptor surface and local membrane structures [2]. Conse-
quently, the activated receptor may seek out membrane nanodomains with altered lipid
content and hydrophobicity, and receptor oligomer assembly may be favored through stable
interactions between complementary hydrophobic TM helix interfaces. Accordingly, our data
show that disruption of membrane lipid organization through cholesterol-depleting MβCD
treatment leads to reductions in agonist-induced GLP-1R clustering. Similarly, we found that
the palmitoylation-deficient GLP-1R C438A mutant was less likely to be found in membrane
rafts when activated. Palmitoylation is widely considered a dynamic raft-targeting mechanism
for GPCRs, as the attached acyl chains anchor the receptor via its C-terminus in lipid-rich
membrane regions [17,68]. Notably, membrane-localized palmitoyl acyltransferase enzymes
and protein thioesterases can themselves be palmitoylated [69] and might therefore be prefer-
entially situated in rafts. With this in mind, it is plausible that receptor oligomerization, clus-
tering, and palmitoylation could be mutually augmented, which could explain why residual
exendin-4-induced clustering was observed both after MβCD treatment and with the GLP-1R
C438A palmitoylation-null mutant. Nevertheless, there are many examples of palmitoylated
proteins that are not raft-associated [69], including the commonly used non–raft marker
transferrin receptor, and raft partitioning of certain palmitoylated proteins such as caveolin-1
is not affected after removal of its palmitoylation sites by mutagenesis [10], highlighting the
multifactorial and complex nature of this process.
1 h preincubation). Nuclei (DAPI), blue; size bars, 10 μm. (G) TIRF microscopy analysis of plasma membranes from MIN6B1 SNAP-GLP-1R
cells transiently transfected with AP2-HA, following labeling with SNAP-Surface 488 (green) and stimulation for 1 min with 100 nM exendin-
phe1 with and without BETP (10 μM), prior to fixation and HA-tag immunofluorescence (red); size bars, 2 μm. (H) Representative electron
micrographs depicting different stages of CCP endocytosis of gold-labeled SNAP-GLP-1Rs (red arrows) in MIN6B1 SNAP-GLP-1R cells
stimulated for 1 min with 100 nM exendin-phe1 with BETP (10 μM); size bars, 100 nm. All data are shown as mean ± SEM. Underlying raw
data for all the panels included in this figure can be found in S1 Data; uncropped blots from this figure can be found in S1 Raw Images. AP2,
activator protein 2; BETP, 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; CCP, clathrin-coated pit; FITC, fluorescein
isothiocyanate; GLP-1R, glucagon-like peptide-1 receptor; HA, hemagglutinin; HEK293, human embryonic kidney 293; MβCD, methyl-β-
cyclodextrin; TIRF, total internal reflection fluorescence; wt, wild type.
https://doi.org/10.1371/journal.pbio.3000097.g008
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Modulation of GPCR posttranslational modifications, as well as receptor clustering and
recruitment to specific plasma membrane nanodomains, have all previously been suggested as
means by which biased signaling can be regulated [58]. We found marked differences in GLP-
1R clustering and nanodomain recruitment between biased exendin-4-based agonists previ-
ously shown by us to exhibit significant differences in receptor binding affinity and signaling
preference [22], as well as distinct GLP-1R palmitoylation profiles as shown in this study.
Related to this, our single-molecule tracking analysis also demonstrates that the plasma mem-
brane lateral diffusion of GLP-1R molecules is altered upon agonist binding, with high-affinity
agonists decreasing the average diffusion coefficient of the receptor, as recently reported for
the closely related class B GPCR glucagon receptor (GCGR) [70], whereas the lower-affinity
biased agonist exendin-phe1 causes virtually no change. Although we did not determine the
structural basis for these distinct behaviors, it seems plausible that specific TM helix rearrange-
ments stabilized by different agonists, as previously reported for the GLP-1R [71], could affect
how the receptor interacts with other membrane constituents via phenomena discussed in the
previous paragraph.
The observation that these effects are recapitulated to a certain extent by the palmitoyla-
tion-null C438A GLP-1R mutant suggests a partial role for this posttranslational modification
in the establishment of signal bias. However, the observed reductions in receptor clustering,
raft segregation, and signaling, as well as the reduction in β-arrestin recruitment and GLP-1R
internalization, were milder with the latter compared to exendin-phe1. Additionally, allosteric
augmentation of agonist residence time with the GLP-1R-specific PAM BETP is in itself capa-
ble of inducing nanodomain clustering. BETP is able, as shown here, of exerting its effects
while at the same time inhibiting GLP-1R palmitoylation, the latter presumably because of
its covalent binding to GLP-1R cysteine 438 [55], which would block any posttranslational
modification at this residue. Whether binding of BETP at cysteine 438 or at other alternative
cysteine sites could functionally substitute for the absence of palmitic acid at this residue to
promote nanodomain translocation was not formally assessed in the present study, but it
appears improbable that the mechanism is C438-specific, as the effect of BETP on GLP-1R
endocytosis was preserved in the GLP-1R C438A mutant, which was also previously reported
to show normal potentiation of partial agonist signaling responses in contrast to C347A [55].
Taken together, the above considerations suggest that the control of GLP-1R recruitment to
membrane nanodomains and its associated effects on receptor signaling are likely to encom-
pass contributions from various factors.
As well as receptor conformational changes influencing interactions with plasma mem-
brane lipids, the converse can also be true. For example, binding to a specific raft lipid has
been shown to allosterically change the conformation of the human epidermal growth factor
(EGF) receptor [72], and interactions with cholesterol can increase the binding affinity of cer-
tain GPCRs [73], with molecular dynamics simulations suggesting that cholesterol allosteri-
cally modulates receptors by limiting their conformational flexibility [74]. Thus, functional
association of GLP-1R with membrane rafts might potentially induce specific conformational
changes that could modulate its agonist binding properties. In this context, receptor clustering
associated with nanodomain segregation might dynamically influence ongoing agonist bind-
ing events. Firstly, cross talk within oligomeric complexes is known to alter the binding prop-
erties of individual receptor protomers [75], although this typically manifests as negative
cooperativity, i.e., with secondary protomers displaying reduced affinity, as previously
described for GLP-1R constitutive homodimers [37]. Alternatively, aggregation of receptors
within specific membrane regions could shift the behavior of a dissociating agonist toward
rebinding to a nearby available receptor rather than diffusing away into the extracellular space
[76]. Apparent support for the latter phenomenon was provided by our cholesterol depletion
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studies in exendin-4-stimulated conditions, in which an association was seen between reduced
GLP-1R clustering and reduced binding affinity for exendin-4. However, examining this fur-
ther using two agonists (exendin-4 and exendin-phe1) with opposing clustering capabilities
and bidirectional manipulation of this process with BETP and MβCD provided mixed results.
Specifically, the former selectively enhanced exendin-phe1 binding, whereas the effect of
the latter was equal for both agonists. The likelihood that these manipulations affect multiple
nonoverlapping cellular processes beyond their effects on receptor clustering, potentially
including direct allosteric control of binding events by cholesterol [77], may underlie these
discrepancies.
Membrane nanodomains are thought to compartmentalize cellular processes by contribut-
ing to the organization of signaling molecules. Our observation that the main GLP-1R signal
transducer, GαS, is predominantly raft-associated in beta cells underlines the importance of
agonist-induced GLP-1R nanodomain segregation in the optimization of GLP-1R signaling,
with disturbances in this process predicted to carry deep consequences for the control of insu-
lin secretion, as illustrated in the present study by the acute signaling and insulin secretion
defects harbored by the C438A palmitoylation-null mutant. Interestingly, the same agonist
dependency for either palmitoylation or membrane raft recruitment was not found with the
closely related GIPR, which has a higher constitutive activity in the absence of agonist stimula-
tion [78]. Although we did not examine this possibility, local control of cAMP and PKA signal-
ing might involve A-kinase anchoring proteins (AKAPs) [79]. For example, the AKAP79/150
signaling complex [80], known to be palmitoylated and targeted to lipid raft domains [81] and
therefore likely to be in close apposition to activated GLP-1Rs, increases GLP-1-induced insu-
lin secretion through anchoring of multifunctional protein phosphatases [82].
Interestingly, despite being recruited to lipid rafts in response to agonist stimulation, the
GLP-1R appears to follow a clathrin-dependent pathway of internalization. Additionally, we
found that presence of cholesterol was required to ensure efficient GLP-1R endocytosis, as
demonstrated by the inhibition of agonist-induced GLP-1R internalization following choles-
terol extraction with MβCD. This phenotype correlated with concomitant reductions in ago-
nist binding affinity and GLP-1R clustering upon MβCD exposure, with all these effects
triggered at similar MβCD concentrations. Cholesterol extraction is known to inhibit both
clathrin-dependent [83,84] and clathrin-independent [85] pathways of endocytosis, as, to vary-
ing extents, all endocytosis pathways are sensitive to cholesterol depletion, with some of them
also being interconnected [86,87]. It can therefore be technically challenging to distinguish
between endocytic pathways and their functional reliance on membrane nanodomains, with
cholesterol dependency not necessarily an adequate tool to do so [88]. Moreover, the same
raft-associated protein can occasionally be internalized via different pathways [85], and block-
ing one pathway with either a specific chemical inhibitor or using a genetic approach such as
small interfering RNA (siRNA)-mediated depletion of specific endocytic factors can have indi-
rect effects and/or result in the up-regulation of residual pathways as a compensatory mecha-
nism [89]. Although our direct observation of the association of clustered GLP-1Rs with the
clathrin adaptor AP2 as well as presence of gold-labeled GLP-1Rs in CCPs points toward cla-
thrin-mediated endocytosis as the main GLP-1R internalization pathway in beta cells under
normal conditions, it remains to be established whether the receptor can follow alternative
pathways under different contexts and/or cell types.
It is also not yet known how the receptor internalizes from cholesterol-rich membrane
nanodomains. This has previously been described for other raft-associated GPCRs as either
following an atypical clathrin-mediated mechanism [48] or via a sequential association to
membrane rafts and CCPs [90], with raft recruitment preceding CCP incorporation. Addition-
ally, although recruitment of β-arrestins to the GLP-1R occurred preferentially at membrane
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rafts, indicative of a higher level of receptor activation within these nanodomains and presum-
ably associated with the β-arrestin-dependent GLP-1R desensitization previously observed by
us [22], β-arrestins appeared to play a very minor role in GLP-1R endocytosis. It is worth not-
ing that the GLP-1R harbors an AP2-binding domain in its C-terminal tail and can interact
directly with this clathrin adaptor, reducing the need for additional intermediaries [91].
In conclusion, in the present study, we have employed biochemical assays in conjunction
with high-resolution microscopy and spatially localized FRET biosensor experiments to estab-
lish the existence of an agonist-triggered GLP-1R palmitoylation and clustering mechanism
coupled to nanodomain-dependent GLP-1R signaling and internalization. We have also estab-
lished that this mechanism can be controlled by the modulation of agonist binding affinities,
either with biased GLP-1R agonists or with the PAM BETP. Future investigations—including
identification of the specific palmitoyltransferase(s) and palmitoyl protein thioesterase(s)
responsible for the regulation of agonist-induced GLP-1R palmitoylation in beta cells, as well
as use of molecular dynamics simulations, model systems to fine-tune the plasma membrane
lipid composition, and superresolution experiments to examine dynamic changes in GLP-1R
conformation and binding affinities associated with interactions with specific lipid nanodo-
mains at a single-molecule level in real time [5,92]—will all be required to further develop our
understanding of the impact of membrane lipid composition on the spatiotemporal organiza-
tion of GLP-1R signaling.
Materials and methods
Ligands
GLP-1(7–36)NH2, exendin-4, and exendin(9–39) were from Bachem, and custom peptides
were from Insight Biotechnology. TMR and FITC conjugates of exendin-4 and/or exendin-
phe1 and exendin(9–39) were coupled via K12, as previously described [22]. BETP was from
Sigma-Aldrich.
Cell culture and generation of stable cell lines
HEK293 cells (ECACC) were maintained in DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. CHO-K1 cells (ECACC) were maintained in
DMEM supplemented with 10% FBS, 20 mM HEPES, 1% nonessential amino acids, and 1%
penicillin/streptomycin. PathHunter CHO-GLP-1R β-arrestin-2 reporter cells (DiscoverX)
were maintained in the manufacturer’s Culture Medium 6. HEK293 β-arrestin-2-EA cells
were generated by infection of HEK293 cells with viral retroparticles expressing β-arrestin-2
fused to EA (DiscoverX) and selected in hygromycin. Parental INS-1 832/3 cells and INS-1
832/3 cells with endogenous GLP-1R or GIPR deleted by CRISPR/Cas9 (a gift from Dr. Jacqui
Naylor, MedImmune) [40] were maintained in RPMI-1640 at 11 mM D-glucose, supple-
mented with 10% FBS, 10 mM HEPES, 2 mM L-glutamine, 1 mM pyruvate, 50 μM β-mercap-
toethanol, and 1% penicillin/streptomycin. MIN6B1 cells (a gift from Prof. Philippe Halban,
University of Geneva, Switzerland) were maintained in DMEM at 25 mM D-glucose supple-
mented with 15% FBS, 50 μM β-mercaptoethanol, and 1% penicillin/streptomycin. MIN6B1
cells with deleted endogenous GLP-1R expression were generated by CRISPR/Cas9 as follows:
cells were cotransfected with the CRIPSR/Cas9 vector pX330-U6-Chimeric_BB-CBh-hSpCas9
(a gift from Prof. Feng Zhang, Addgene plasmid #42230) with cloned guide RNA sequence 50-
CCCCGAGCAGCAGGAGCGCC-30 targeting the minus strand of mouse GLP-1R exon 1 and
pcDNA3.1+ and selected in 1 mg/ml G418. A mixed population of cells was recovered and cul-
tured without further G418 selection. Stable SNAP-GLP-1R-expressing HEK293 cells (wild
type and β-arrestin-less [52]) were generated by transfection of pSNAP-GLP-1R (Cisbio) and
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G418 (1 mg/ml) selection. The same approach was used to generate HEK293 cells stably
expressing N-terminal FLAG-tagged GLP-1R and to reintroduce stable expression of wild-
type or C438A mutant SNAP-GLP-1R into INS-1 832/3 cells lacking endogenous GLP-1R
expression. Stable SNAP-GLP-1R CHO-K1 and MIN6B1 cells were described previously [22].
Mycoplasma testing was performed yearly.
Generation of SNAP-GLP-1R C438A and PK-tagged SNAP-GLP-1R wild-
type and C438A vectors
SNAP-GLP-1R C438A mutant vector was generated from wild-type SNAP-tagged human
GLP-1R by site-directed mutagenesis with the QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent), following the manufacturer’s instructions. PK-tagged variants of both SNAP-
GLP-1R wild-type and C438A vectors were generated for β-arrestin-2 recruitment assays by
cloning of HindIII–BglII restriction fragments onto the pCMV-ProLink 1 Vector (DiscoverX).
MβCD treatments
Cells were treated with MβCD (Sigma-Aldrich) at the indicated concentration in HBSS or
media without serum. MβCD treatments were washed off before stimulation, with the excep-
tion of the time-lapse confocal microscopy and the TR-FRET assays performed with multiple
MβCD concentrations, in which for practical reasons, MβCD was left on the cells during ago-
nist treatment. When relevant, MβCD treatments were performed after labeling with SNAP-
Surface fluorescent probes.
Fluorescent labeling and biochemical quantification of cellular cholesterol
Cells were treated with or without MβCD as above. For cholesterol labeling, filipin staining
was carried out with the Cell-Based Cholesterol Assay Kit (Abcam). For quantification of cho-
lesterol levels, lipid was extracted using butanol as described [93]. Briefly, the washed cell pellet
was left in 250 μl butanol overnight at 4 ˚C, and the organic layer was aspirated, placed in a
microplate, and allowed to evaporate to dryness. The lipid film was redissolved in 1% Triton
X-100, and cholesterol concentration was determined using the Amplex Red Cholesterol
Assay Kit (Thermo Fisher), followed by normalization to protein content of the cell pellet
determined by BCA assay.
Cell labeling for EM
SNAP-GLP-1R-expressing cells cultured on Thermanox coverslips (Agar Scientific) were
labeled with 2 μM cleavable SNAP-Surface biotin probe in full media, followed by 5 μg/ml
NaN3-free Alexa Fluor 488 Streptavidin, 10 nm colloidal gold conjugate (Thermo Fisher) in
HEPES-bicarbonate buffer (120 mM NaCl, 4.8 mM KCl, 24 mM NaHCO3, 0.5 mM Na2HPO4,
5 mM HEPES, 2.5 mM CaCl2, and 1.2 mM MgCl2, saturated with 95% O2/5% CO2 [pH 7.4]),
and 1% BSA and stimulated with the indicated treatment. Conventional EM was performed as
described. Briefly, cells were fixed, processed, mounted on Epon stubs, and polymerized at 60
˚C, and 70-nm sections were cut en face with a diamond knife (DiATOME) in a Leica Ultracut
UCT ultramicrotome before examination on an FEI Tecnai G2-Spirit TEM. Images were
acquired in a charge-coupled device camera (Eagle) and processed in Fiji.
EM quantification of clustering by plasma membrane rip-offs
Cells expressing SNAP-GLP-1R were cultured on Thermanox coverslips and gold-labeled with
SNAP-Surface biotin followed by AlexaFluor 488 Streptavidin, 10 nm colloidal gold conjugate
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as above. Cells were stimulated with the indicated treatments for 1 min. Membrane rip-offs
were performed following the protocol of Sanan and Anderson [94]. In brief, EM grids were
coated with formvar and poly-L-lysine, and cell coverslips were inverted on top with pressure
applied for approximately 10 s at 4 ˚C. This allowed detachment of the apical cellular mem-
branes onto the grids, which were immediately fixed by incubating in 4% glutaraldehyde in 25
mM HEPES buffer for 15 min. The grids were subsequently prepared for EM analysis by post-
fixation in 2% aqueous osmium followed by 1% aqueous tannic acid and 1% aqueous uranyl
acetate, for 10 min each at room temperature, and examined on a JEOL 1400+ TEM with
images taken on an AMT digital camera. Gold-particle nearest-neighbor analysis was per-
formed using ImageJ.
Cell labeling, confocal, and TIRF microscopy
For confocal microscopy, cells were labeled at 37 ˚C with 1 μM of the indicated SNAP-tag fluo-
rescent probe (New England Biolabs) in full media, stimulated with agonists for the indicated
times, fixed in 4% paraformaldehyde, mounted in Prolong Diamond antifade reagent with
4,6-diamidino-2-phenylindole (Life Technologies), imaged with a Zeiss LSM-780 inverted
confocal laser-scanning microscope in a ×63/1.4 numerical aperture oil-immersion objective
from the Facility for Imaging by Light Microscopy (FILM) at Imperial College London, and
analyzed in Fiji. For TIRF microscopy, SNAP-GLP-1R-expressing cells were transfected
with μ2-HA-WT (a gift from Prof. Alexander Sorkin, Addgene plasmid #32752), plated on
glass-bottom MatTek dishes, labeled with SNAP-Surface 488 probe as above, stimulated or not
for 2 min with the indicated agonist, and fixed as above before immunofluorescence with a
mouse monoclonal anti-HA (HA-7) antibody (catalogue no. H3663, Sigma), followed by a
secondary AlexaFluor 546 antibody. Unmounted samples in PBS were imaged using a Nikon
Eclipse Ti microscope equipped with a ×100/1.49 numerical aperture TIRF objective, a TIRF
iLas2 module, and a Quad Band TIRF filter cube (TRF89902, Chroma). Images were acquired
with an ORCA-Flash 4.0 camera (Hamamatsu) and Metamorph software (Molecular Devices),
and colocalization was measured by Manders’ coefficient analyzed using Coloc 2 plugin in Fiji.
Analysis of SNAP-GLP-1R internalization and fluorescent exendin-4
conjugate uptake by time-lapse confocal microscopy
To assess dynamic internalization profiles of the SNAP-GLP-1R, cells were plated onto glass-
bottom MatTek dishes and labeled with SNAP-Surface 549 prior to imaging using the same
confocal system as above in HBSS at 37 ˚C for 10 min at 0.33 frames s−1 immediately after
stimulation with 100 nM exendin-4. For ligand uptake measurements, unlabeled cells were
stimulated with 100 nM exendin-4-K12-TMR. Levels of surface SNAP-GLP-1Rs or exendin-
4-K12-TMR were analyzed using a custom algorithm. Briefly, intensity profiles were obtained
from three separate segments across the plasma membrane of individual cells for every 10th
frame. Peak intensities were calculated from these segments and averaged. Data was normal-
ized to baseline at time 0 for each individual acquisition and plotted over time. Area under the
curve (AUC) was calculated from kinetic traces to compare internalization propensities.
Clustering measurements by TIRF-PALM
For TIRF-PALM analysis of FLAG-GLP-1R cluster sizes, the GLP1R-Tango vector (a gift from
Prof. Bryan Roth, Addgene plasmid #66295), which harbors a single N-terminal FLAG tag,
was used to introduce a STOP codon at the end of the GLP-1R coding sequence by site-
directed mutagenesis performed as above. HEK293 cells were used to generate a subline with
stable expression of the engineered FLAG-GLP-1R construct as above. Cells were subsequently
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plated onto glass-bottom MatTek dishes and labeled with the anti-FLAG GAGE 500 antibody
(1:500 dilution) described in [95] in 10% FCS in PBS containing calcium and magnesium at 37
˚C for 30 min. Cells were washed in PBS containing calcium and magnesium and stimulated
or not with 100 nM exendin-4 for 2 min prior to fixation for 30 min in 4% paraformaldehyde
with 0.2% glutaraldehyde to minimize antibody-induced clustering artifacts. Following fixa-
tion, cells were washed in PBS with calcium and magnesium and maintained in the same
buffer for imaging. All steps were carried out in the dark to ensure minimal label photo-
switching. Images were acquired using a Zeiss Elyra PS1 featuring an AxioObserver Z1 motor-
ized inverted microscope with TIRF capability with an Alpha Plan-APO ×100/1.46 numerical
aperture oil-immersion objective at the Imperial College London FILM facility. Photo-conver-
sion of CAGE 500 was achieved with a 405-nm light source and simultaneously imaged and
photo-bleached with a 488-nm laser line. The microscope was contained in a plastic draft-
proof enclosure maintained at a constant temperature of 25 ˚C and mounted on a vibration
isolation table. Laser lines were switched on at least 1 h prior to imaging to allow stabilization
of the system in order to ensure minimal sample drift throughout the imaging. Each TIRF-
PALM time series was acquired using a cooled electron-multiplying charge-coupled device
camera (EM-CCD; iXon DU 897, Andor Technology) and LMS Zen operating software with
an exposure time of 30 ms. Localization of receptors was determined using QuickPALM Fiji
plugin: fluorescent images of cropped nonoverlapping areas of 7 × 7 μm within cell borders
were analyzed using a full-width half-maximum value of 4 and signal-to-noise ratio of 8. Ana-
lyzed areas did not span cell membranes, to exclude any potential biasing resulting from edge
effects. Data tables containing particle-localization 2D coordinates were generated. The num-
ber of associated receptor molecules from these coordinates was determined with PD-Interpr-
eter as in [95] with a 50-nm radius from each fluorophore. To discount any overestimation of
oligomers, events within a 10-nm radius of an activated fluorophore were discounted from the
analysis.
Single-molecule localization microscopy
CHO-K1 cells were cultured in phenol red-free DMEM/F12, supplemented with 10% FBS at
37 ˚C with 5% CO2 and seeded onto 25-mm clean glass coverslips at a density of 3 × 105 cells
per well. The following day, cells were transfected with SNAP-GLP-1R, labeled 4 h after trans-
fection with 1 μM SNAP-Surface 549 for 20 min in complete medium, washed and imaged in
culture medium at 37 ˚C using a custom-built TIRF microscope (Cairn Research) based on
an Eclipse Ti2 (Nikon, Japan) equipped with four EMCCD cameras (iXon Ultra, Andor), a
561-nm diode laser, and a ×100/1.49 numerical aperture oil-immersion objective (Nikon).
Cells were stimulated with either vehicle or 100 nM exendin-4, exendin-phe1, or exendin-asp3
for 10–15 min. Single-molecule image sequences were acquired every 30 ms. Image sequences
were analyzed with an automated particle detection and tracking algorithm (u-track) [59] in
the MATLAB environment and further investigated using custom algorithms, as previously
described [59,60]. To analyze the motion of receptors, the time-averaged MSD (TA-MSD)
[96] of individual trajectories from TIRF image sequences was computed as previously
described [60], and fitted with the following equation:
TA-MSDðtÞ ¼ 4Dta þ 4serr
2
where t indicates time, α is the anomalous diffusion exponent, and σerr is a constant offset for
localization error. Only trajectories lasting at least 100 frames were analyzed and categorized
according to the diffusion parameters D and α. Particles with D < 0.01 μm2 s−α were consid-
ered immobile. Normal diffusion was assigned to particles with D� 0.01 μm2 s−α and 0.75�
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α� 1.25. Sub- and superdiffusion were assigned to particles with D� 0.01 μm2 s−α and α<
0.75 or α> 1.25, respectively.
Clustering measurements by TR-FRET
Cells stably or transiently expressing SNAP-GLP-1R were dual-labeled with the TR-FRET
probe SNAP-Lumi4-Tb (40 nM, Cisbio) and SNAP-Surface 647 (1 μM, New England Biolabs)
for 60 min at room temperature. These concentrations were selected because they provided
optimum signal intensity at both measurement wavelengths. Where relevant, MβCD treat-
ments were performed after labeling. Cells were washed and placed in HBSS in a white plate
for a 10-min baseline measurement at 37 ˚C using a Spectramax i3x (Molecular Devices) plate
reader fitted with a TR-FRET filter set (λEx = 335 nm, λEm = 616 nm and 665 nm, delay 30 μs,
integration time 400 μs). TR-FRET was sequentially measured after agonist addition. The ratio
of fluorescent signals at both emission wavelengths (665/616) was considered indicative of
clustering because it reflects both transient and stable interactions between receptor protomers
occurring within the long fluorescence lifetime of the excited terbium cryptate. Dose-response
curves were constructed from AUC obtained from kinetic traces at different agonist concen-
trations and fitted to 4-parameter logistic curves to calculate potency (log EC50) and efficacy
(Emax) values.
NR12S assays and analysis
Cells expressing SNAP-GLP-1R were first labeled with SNAP-Lumi4-Tb (40 nM) for 60 min
at room temperature. Where relevant, MβCD treatments were performed after Lumi4-Tb
labeling. For spectral measurements and analysis, (1) washed, Lumi4-Tb-labeled cells were
placed in HBSS in a white plate, and a full baseline TR-FRET spectral scan was performed at
37 ˚C using a Flexstation 3 plate reader (Molecular Devices; λEx = 335 nm, λEm = 460–650
nm in 5-nm steps, no cutoff, delay 50 μs, integration time 300 μs) to detect the Lumi4-Tb-only
signal; (2) freshly prepared NR12S in HBSS (200 nM) was then added, and after a further 5
min, a second spectral scan was performed to detect basal FRET; (3) agonist was added for 5
min, and a final spectral scan was performed to detect agonist-changes in TR-FRET. After an
initial blank subtraction, data were analyzed by ratiometrically normalizing the spectrum from
each read to the signal measured at 490 nm; the normalized Lumi4-Tb-only read was sub-
tracted from subsequent normalized reads to obtain the NR12S-specific TR-FRET signal in the
presence and absence of agonist. Where indicated, the AUC was calculated below and above
the λEm maximum of 590 nm as a marker of relative contributions from liquid-ordered-asso-
ciated (530–590 nm) and liquid-disordered-associated (590–650 nm) SNAP-GLP-1Rs and
expressed relative to the total NR12S TR-FRET AUC (530–650 nm). Alternatively, liquid-
ordered and liquid-disordered FRETs were assigned values of 570 and 610 nm, respectively,
with the NR12S-associated increase at each wavelength ratiometrically expressed to indicate
differences in SNAP-GLP-1R localization in each nanodomain. For kinetic measurements and
analysis, washed, Lumi4-Tb-labeled cells were treated with NR12S at the indicated concentra-
tion, and a 5-min baseline read was performed (λEx = 335 nm, λEm = 490, 570, and 610 nm).
Agonist was then added and changes in TR-FRET sequentially monitored. Signals at each
wavelength were blank-subtracted and expressed ratiometrically to each other, with agonist-
induced changes quantified relative to individual well baseline.
Measurement of GLP-1R binding parameters by TR-FRET
For equilibrium binding assay at multiple MβCD concentrations, cells expressing SNAP-GLP-
1R were first labeled with SNAP-Lumi4-Tb (40 nM) for 60 min at room temperature and
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added to 96-well white plates. MβCD treatments in HBSS were applied for 45 min along with
metabolic inhibitors (20 mM 2-deoxyglucose and 10 mM NaN3) to prevent GLP-1R endocyto-
sis [97]. Exendin-4-K12-FITC or exendin-9-K12-FITC at a final BSA concentration of 0.1%
were applied and allowed to bind at room temperature for 3 h. TR-FRET was then measured
over 10 min at room temperature using a Flexstation 3 plate reader (λEx = 335 nm, λEm = 520
and 620 nm, delay 50 μs, integration time 300 μs). Binding was quantified ratiometrically as a
520/620 signal, and Kd was determined using the Prism saturation binding model “one site–
specific binding”. For kinetic binding assays, cells expressing SNAP-GLP-1R were first labeled
with SNAP-Lumi4-Tb (40 nM) for 60 min at room temperature. Where relevant, MβCD treat-
ments were performed after Lumi4-Tb labeling. After washing, cells were placed in HBSS
+ 0.1% BSA, supplemented with metabolic inhibitors as above, and baseline TR-FRET was
measured over 10 min at 37 ˚C as above. FITC-conjugated agonists were then added, and
TR-FRET was sequentially measured to monitor agonist association. Binding was quantified
ratiometrically as a 520/620 signal, and baseline-subtracted data were analyzed using the
GraphPad Prism model “association kinetics: two or more concentrations of hot” to obtain
association (kon) and dissociation (koff) rate constants, from which the equilibrium binding
constant Kd was determined.
Measurement of GLP-1R internalization by DERET assay
The assay was performed as previously described [22]. Cells expressing SNAP-GLP-1R were first
labeled with SNAP-Lumi4-Tb (40 nM) for 1 h at room temperature. Where relevant, MβCD
treatments were performed after Lumi4-Tb labeling. After washing, cells were placed in HBSS
supplemented with 24 mM fluorescein. A 10-min baseline read at 37 ˚C was taken in a Flexsta-
tion 3 plate reader in TR-FRET mode (λEx = 335 nm, λEm = 520 and 620 nm, delay 400 μs,
integration time 1,500 μs), after which compounds were injected to the wells. Loss of surface
SNAP-GLP-1R was detected as changes over time in the homogenous time-resolved fluorescence
(HTRF) ratio (620/520 signal after blank subtraction at each time point). Dose-response curves
were constructed from AUC obtained from kinetic traces at different agonist concentrations and
fitted to 4-parameter logistic curves to calculate potency (log EC50) and efficacy (Emax) values.
Measurement of FITC-ligand uptake by TR-FRET
Cells expressing SNAP-GLP-1R were first labeled with SNAP-Lumi4-Tb (40 nM) for 60 min
at room temperature. After washing, MβCD treatments in HBSS were added to the cells
directly in 96-well plates for 45 min. Cells were then moved to the cold room to temporarily
arrest endocytic processes before addition of 100 nM exendin-4-K12-FITC or exendin(9–39)-
K12-FITC, which were allowed to bind for 3 h at 4 ˚C to reach a state of quasi-equilibrium.
The plate was then moved directly to a Flexstation 3 plate reader at 37 ˚C to initiate endocyto-
sis of prebound FITC-ligand with the extracellular ligand concentration remaining constant.
TR-FRET signal was monitored as above (λEx = 335 nm, λEm = 520 and 620 nm, delay 50 μs,
integration time 300 μs) over 30 min. Here, entry to the endosomal pathway leads to dissocia-
tion of labeled receptor-ligand complexes, resulting in a reduction in TR-FRET signal. The
acidic endosomal pH also reduces inherent FITC fluorescence. Net ligand uptake was there-
fore calculated as the AUC for change in TR-FRET signal throughout the 30-min assay period.
HTRF cAMP measurements
Cells were treated in white microplates with agonist, with or without isobutylmethylxanthine
(IBMX) as indicated to inhibit phosphodiesterases, for the indicated period of time before
total cellular cAMP determination by HTRF (Cisbio cAMP Dynamic 2).
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Measurement of β-arrestin-2 recruitment by PathHunter assay
Cells were treated with agonist or drug at the indicated concentration for the indicated time
periods before lysis and/or membrane fractionation and detection of β-arrestin-2 recruitment
by the PathHunter enzyme fragment complementation assay (DiscoverX) according to the
manufacturer’s instructions.
Real-time measurement of cAMP production and PKA activation using
FRET biosensors
The TEpacVV biosensor was a gift from Dr. K. Jalink, The Netherlands Cancer Institute. The
AKAR4-NES and AKAR4-Lyn biosensors were gifts from Dr Jin Zhang (Addgene plasmid
#61620). Cells expressing SNAP-GLP-1Rs were transiently transfected with the relevant bio-
sensor plasmid for 36 h prior to the assay and placed in HBSS in 96-well clear-bottom black
plates. After a 5-min baseline read at 37 ˚C (λEx = 440 nm, λEm = 485 and 535 nm) in a Flex-
station 3 plate reader, compounds were injected to each well, and sequential readings immedi-
ately commenced. FRET was expressed ratiometrically as signal at 535 nm divided by signal at
485 nm. Individual well responses were normalized to baseline to reduce variability. Dose
responses were either analyzed by obtaining the cumulative AUC relative to baseline over a
fixed time period, or at each time point, or time bin, to allow kinetic comparisons of agonists
between each pathway. To determine agonist-related biased signaling between each biosensor,
the relative potency ratio approach was taken, as all compounds were full agonists in each
pathway measured [98]. Dose-response curves were constructed for each agonist at indicated
time points, and log EC50 values for exendin-phe1 and exendin-asp3 responses in each path-
way were subtracted from those of reference agonist exendin-4 to generate normalized potency
estimates (ΔLog EC50), followed by subtraction of the test pathway (AKAR4-Lyn) from the ref-
erence pathway (AKAR4-NES or TEpacVV) to provide the bias estimate (ΔΔLog EC50). As all
agonists in each pathway were measured in parallel during the same experiment using the
same stock of serially diluted ligand, experiment-specific ΔLog EC50 and ΔΔLog EC50 values
could be produced without requiring error propagation [22].
Insulin secretion assays
INS-1 832/3 cells with endogenous GLP-1R expression deleted by CRISPR/Cas9 (INS-1 832/3
GLP-1R−/−) stably expressing wild-type or C438A SNAP-GLP-1Rs were preincubated over-
night in 3 mM glucose medium. Exendin-4 was added in complete medium at 11 mM glucose
at the time of seeding into plates. After 16 h of incubation, samples were obtained for secreted
insulin and analyzed by HTRF (Cisbio). Results were normalized as a fold increase compared
to cells treated with 11 mM glucose alone.
Palmitoylation assays
For the detection of palmitoylated GLP-1Rs, cells were stimulated with 100 nM of the indi-
cated agonist for 10 min and, when appropriate, pretreated with 10 μM BETP for 5 min (and
throughout the agonist stimulation period) or overnight with 200 μM of the palmitoylation
inhibitor 2-BP. Isolation of palmitoylated proteins was performed with the CAPTUREome
S-Palmitoylated Protein Kit (Badrilla), following the manufacturer’s instructions. The assay is
based on the acyl-resin assisted capture method, described in detail elsewhere [99]. Key steps
include blocking of free thiol groups with a blocking reagent, cleavage of thioester linkages to
release the palmitate group, and capture of newly liberated thiols with the CAPTUREome cap-
ture resin. Briefly, cells were lysed and free thiols blocked in the manufacturer’s blocking buffer
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at 40 ˚C for 4 h with constant vortexing. Proteins were then precipitated with cold acetone for
20 min at −20 ˚C. Following centrifugation at 16,000g for 5 min, the pellet was extensively
washed with 70% cold acetone and resuspended in the manufacturer’s binding buffer. Approx-
imately 10% of the soluble lysate was saved as the input fraction (IF). Prewashed CAPTURE-
ome capture resin was added to the lysates. To this mixture, either the thioester cleavage or the
acyl-preservation reagents were added. Resins were washed five times with the manufacturer’s
binding buffer. Urea sample buffer (100 mM Tris-HCl [pH 6.8], 2.5% SDS, 4 M urea, 50 mM
dithiothreitol, 0.05% bromophenol blue) was used to elute captured proteins from the resin.
Eluted samples were incubated at 37 ˚C for 30 min before western blotting for SNAP-GLP-1R
to detect the fraction of palmitoylated versus nonpalmitoylated receptor. Resin-bound proteins
treated with the thioester cleavage reagent are referred to as the cleaved bound fraction (cBF)
and represent the fraction of palmitoylated proteins, whereas resin-bound proteins treated
with the acyl-preservation reagent are referred to as the preserved bound fraction (pBF) and
are used as negative control for the assay. Corresponding unbound fractions are known as the
cleaved unbound fraction (cUF) and the preserved unbound fraction (pUF).
Detergent-resistant and detergent-soluble membrane fractionation
For membrane raft purification experiments, the cells were seeded onto 10-cm dishes and
transiently transfected with GαS-YFP (a gift from Catherine Berlot, Addgene plasmid
#55781) when indicated. After the indicated treatments, cells were osmotically lysed in 20
mM Tris-HCl (pH 7.0) supplemented with cOmplete EDTA-free protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail 2 (Sigma-Aldrich). The cell suspension was
homogenized by passing through a 22-gauge needle and ultracentrifuged at 63,000g for 1 h at
4 ˚C with a Sorvall Discovery M120 ultracentrifuge. The supernatant was discarded, and the
pellet resuspended in ice-cold PBS supplemented with protease inhibitor cocktail and an ali-
quot retained for total membrane fraction (TMF) analysis. PBS was added to a final volume
of 1 ml, and the suspensions were ultracentrifuged at 63,000g for 30 min at 4 ˚C. The super-
natant was discarded, and the pellet was resuspended in ice-cold PBS supplemented with 1%
Triton-X100 and protease inhibitor cocktail and incubated for 30 min at 4 ˚C. Samples were
ultracentrifuged again at 63,000g for 1 h at 4 ˚C. The supernatant, containing the DSF, was
retained for analysis, and the DRF pellet was resuspended in 1% SDS with protease inhibitor
cocktail. All the samples were sonicated with the Ultrasonic cell disruptor XL-2000 probe
sonicator (Misonix) and centrifuged at 14,000g for 5 min at 4 ˚C before analysis by
SDS-PAGE and western blotting. For measurement of β-arrestin-2 recruitment to different
membrane regions, purified fractions from PathHunter CHO-GLP-1R cells, prepared as
above after vehicle or exendin-4 treatment, were diluted in HBSS and measured using Path-
Hunter chemiluminescent reagents.
SDS-PAGE and western blotting
Samples were separated by SDS-PAGE on 10% gels under reducing conditions and immuno-
blotted onto PVDF membranes (GE Healthcare) and bands detected by enhanced chemilumi-
nescence (GE Healthcare) onto films developed on a Xograph Compact X5 processor.
Antibodies for western blotting were anti-flotillin-1 mouse monoclonal antibody, catalogue
no. sc-74566, Santa Cruz Biotechnology (1:200 dilution); anti-flotillin-1 rat monoclonal anti-
body, catalogue no. 849802, BioLegend (1:100 dilution); anti-SNAP-tag rabbit polyclonal
antibody, catalogue no. P9310S, New England Biolabs (1:500 dilution); anti-GFP mouse
monoclonal antibody, catalogue no. G6795, Sigma (1:1,000 dilution); anti-human transferrin
receptor mouse monoclonal antibody, catalogue no. G1/221/12, Developmental Studies
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Hybridoma Bank (DSHB; 0.2 μg/ml); anti-human GLP-1R mouse monoclonal antibody, cata-
logue no. Mab 3F52, DSHB (0.2 μg/ml); anti-mouse GLP-1R mouse monoclonal antibody, cat-
alogue no. Mab 7F38, DSHB (0.2 μg/ml); and anti-α-tubulin mouse monoclonal antibody,
catalogue no. T5168, Sigma (1:1000 dilution). All uncropped blots showing results included in
the manuscript can be found in S1 Raw Images.
Dose-response data and statistical analyses
Statistical significance was assessed using Student’s t test or ANOVA as indicated, with
matched analyses performed where possible. Curve fitting and statistical analyses were per-
formed using GraphPad Prism 8.0. Statistical significance was taken as p< 0.05. Unless indi-
cated, values represented are the mean ± SEM. Dose-response summaries for all the relevant
manuscript figures are included in S1–S7 Tables.
Supporting information
S1 Fig. Agonist-induced SNAP-GLP-1R clustering and recruitment to membrane nano-
domains—Extra data. (A) Western blotting analysis of SNAP-GLP-1R in lysates from
MIN6B1 SNAP-GLP-1R cells incubated overnight with the indicated amount of tunicamy-
cin, a drug that blocks N-linked glycosylation, showing that the two predominant bands
detected for SNAP-GLP-1R at approximately 75 and 65 kDa correspond to differentially gly-
cosylated forms of the receptor. Tubulin is shown as a loading control. (B) Confocal analysis
of surface and total SNAP-GLP-1R levels in MIN6B1 SNAP-GLP-1R cells following over-
night incubation in vehicle or 10 μg/ml tunicamycin. Surface SNAP-GLP-1R labeled with
SNAP-Surface 488, green; total SNAP-GLP-1R labeled with SNAP-Cell TMR-Star, red;
nuclei (DAPI), blue; size bars, 100 μm. (C) Level of SNAP-GLP-1R in DRFs isolated from
MIN6B1 SNAP-GLP-1R cells treated with vehicle, exendin-4 or GLP-1 for 2 min, with flotil-
lin as a marker of membrane raft loading. Fold increase versus vehicle = 1.96 ± 0.11 for 1 nM
exendin-4, 2.02 ± 0.11 for 10 nM exendin-4, and 2.08 ± 0.23 for 100 nM GLP-1. (D) Cartoon
explaining NR12S assay to monitor SNAP-GLP-1R translocation to membrane nanodo-
mains. (E) TR-FRET spectra in Lumi4-Tb-labeled HEK SNAP-GLP-1R cells treated sequen-
tially with 1 μM NR12S and 100 nM exendin-4, normalized to signal at 490 nm, n = 3. (F)
NR12S-associated TR-FRET spectra in Lumi4-labeled HEK293 SNAP-GLP-1R cells treated
with the indicated concentrations of exendin-4 or vehicle, Lumi4-Tb-only spectrum has
been subtracted, and spectrum divided into Lo (530–590 nm) and Ld (590–650 nm) regions,
n = 6; error bars not shown for clarity. (G) Proportional change in Lo-associated (left) or Ld-
associated (right) SNAP-GLP-1R-NR12S TR-FRET induced by exendin-4, determined from
(F) as percentage of total AUC from 530–590 nm or 590–650 nm portions of the spectrum,
respectively, 3-parameter fits of pooled data shown. (H) Alternative analysis of data from (F),
with TR-FRET increase after Lumi4-Tb-only subtraction quantified at 570 nm and 610 nm
and expressed ratiometrically to indicate increased localization of SNAP-GLP-1R in Lo
phase, 3-parameter fit of pooled data shown. All data are shown as mean ± SEM except
where indicated. (I) Further examples of electron micrographs showing clusters of gold-
labeled SNAP-GLP-1Rs (arrows) from 2D plasma membrane sheets isolated from MIN6B1
cells stably expressing SNAP-GLP-1R following SNAP-tag gold labeling and treatment with
100 nM exendin-4 for 2 min; size bars, 100 nm. Underlying raw data for all the panels
included in this figure can be found in S2 Data; uncropped blots from this figure can be
found in S1 Raw Images. AUC, area under the curve; DRF, detergent-resistant fraction;
GLP-1R, glucagon-like peptide-1 receptor; HEK, human embryonic kidney; Ld, liquid-disor-
dered; Lo, liquid-ordered; TMR, 5-Carboxytetramethylrhodamine; TR-FRET, time-resolved
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Fo¨rster resonance energy transfer.
(EPS)
S2 Fig. Effects of inhibition of nanodomain compartmentalization on GLP-1R responses—
Extra data. (A) Cholesterol levels determined by filipin staining (left) in CHO SNAP-GLP-1R
cells after SNAP-Surface 549 labeling (right) treated with vehicle, MβCD (10 mM), or MβCD
saturated with cholesterol for 1 h as a control; size bars, 10 μm. (B) Biochemical quantification
of cholesterol depletion by MβCD in HEK293, CHO-K1, INS-1 832/3, and MIN6B1 cells
treated for 45 min with 10 mM MβCD (3 mM for CHO-K1 cells) followed by butanol extrac-
tion and cholesterol quantification and normalization to protein content, n = 3. (C) Lack
of effect of MβCD (10 mM, 45 min) treatment on surface labeling by Lumi4-Tb in HEK
SNAP-GLP-1R cells, measured as TR-FRET at 550 nm and normalized for cell count, n = 3.
(D) Equilibrium binding assay showing binding of exendin-4-K12-FITC to INS-1 832/3 GLP-
1R−/− SNAP-GLP-1R cells treated with indicated concentration of MβCD (45 min), n = 5. (E,
F) Binding traces (E) and corresponding association (kon) and dissociation (koff) rate constants
(F) for exendin-4-K12-FITC determined from TR-FRET kinetic binding experiments in INS-1
832/3 GLP-1R−/− SNAP-GLP-1R cells with or without prior cholesterol depletion with MβCD
(10 mM, 45 min), n = 5, paired t test. (G) SNAP-GLP-1R clustering responses at indicated
dose of exendin-4 in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells with and without prior
treatment with MβCD (10 mM, 45 min), expressed as fold increase from baseline, n = 5. (H)
Dose-response analysis of MβCD effect on exendin-4-induced liquid-ordered-associated
SNAP-GLP-1R NR12S TR-FRET, calculated as percentage of total AUC from 530–590 nm
portion of spectrum, 3-parameter fit of pooled data shown. (I) Dose responses for exendin-
4-induced TEpacVV and AKAR4-Lyn FRET changes, determined as AUC over 30 min relative
to individual baselines, paired t test used to compare Emax from n = 5 repeats. (J) Confocal
analysis of SNAP-GLP-1R internalization in CHO SNAP-GLP-1R cells labeled with SNAP-
Surface 549 prior to treatment with MβCD (10 mM) or MβCD saturated with cholesterol (as a
control) for 1 h followed by 15-min stimulation with 100 nM exendin-4; size bars, 10 μm. (K)
Time-course internalization, assessed as decrease in plasma membrane (surface) signal, from
time-lapse confocal microscopy data of CHO SNAP-GLP-1R cells labeled with SNAP-Surface
549 for 30 min and treated or not with 10 mM MβCD for 1 h before stimulation with 100 nM
exendin-4. Data normalized to baseline for every individual trace, n = 3; inset, AUC calculated
from main graph with unpaired t test performed. (L) Uptake of exendin-4-K12-FITC or exen-
din(9–39)-K12-FITC in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells pretreated with indicated
concentration of MβCD, measured by TR-FRET, shown normalized to baseline signal, n = 5.
(M) Time-course exendin-4-K12-TMR uptake, assessed as decrease in surface signal from
time-lapse confocal microscopy data of INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells pretreated
with the indicated MβCD concentration for 1 h. Data normalized to baseline for every individ-
ual trace, n = 6 traces from three time-lapse recordings per condition. �p< 0.05, ��p< 0.01,
“ns” indicates nonsignificant, by statistical test indicated in the text. Data are shown as
mean ± SEM, with individual replicates shown where relevant. Underlying raw data for all the
panels included in this figure can be found in S2 Data, and a dose-response summary for this
figure is included in S6 Table. AUC, area under the curve; CHO, Chinese hamster ovary;
FITC, fluorescein isothiocyanate; GLP-1R, glucagon-like peptide-1 receptor; MβCD, methyl-
β-cyclodextrin; TMR, 5-Carboxytetramethylrhodamine; TR-FRET, time-resolved Fo¨rster reso-
nance energy transfer.
(EPS)
S3 Fig. Lack of effect of β-arrestins on exendin-4 binding affinity to the GLP-1R. (A)
TR-FRET kinetic binding data for exendin-4-K12-FITC in wt and βarr1/2 KO cells stably
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expressing SNAP-GLP-1R, n = 4. (G) Association rate (kon), dissociation rate (koff), and equi-
librium dissociation constants (Kd) derived from (A), compared by paired t test, “ns” indicates
nonsignificant. Data are shown as mean ± SEM, with individual replicates shown where rele-
vant. Underlying raw data for all the panels included in this figure can be found in S2 Data.
βarr1/2 KO, β-arrestin-1/2 knockout; FITC, fluorescein isothiocyanate; GLP-1R, glucagon-like
peptide-1 receptor; TR-FRET, time-resolved Fo¨rster resonance energy transfer; wt, wild-type.
(EPS)
S4 Fig. Nanodomain segregation, signaling, and internalization of GLP-1R C438A mutant
—Extra data. (A) Stably expressed SNAP-GLP-1R wt or C438A surface levels (right) and rep-
resentative images (left) in INS1 832/3 GLP-1R−/− cells. SNAP-Surface 488, green; nuclei
(DAPI), blue; size bars, 10 μm. Paired t test. (B) Surface Lumi4-Tb labeling in HEK293 cells
transiently transfected with wt or C438A SNAP-GLP-1R, n = 9, paired t test. (C) TR-FRET
kinetic binding data for exendin-4-K12-FITC in INS1 832/3 GLP-1R−/− cells stably expressing
wild-type or C438A SNAP-GLP-1R, n = 4. (D) Association (kon) and dissociation (koff) rate
constants derived from (C), paired t tests. (E) Wt or C438A SNAP-GLP-1R clustering
responses at indicated dose of exendin-4 in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells, mea-
sured by HTRF and expressed as fold increase from baseline, n = 5. (F) Endogenous level of
GLP-1R expression in lysates from MIN6B1 wt versus GLP-1R−/− cells. Tubulin is shown as a
loading control. (G) Confocal analysis of SNAP-GLP-1R wt versus C438A internalization in
MIN6B1 GLP-1R−/− cells transiently expressing either type of SNAP-GLP-1R following label-
ing with SNAP-Surface 488 for 30 min and stimulation with 100 nM exendin-4 for 15 min.
Nuclei (DAPI), blue; size bars, 10 μm. (H, I) Confocal analysis of SNAP-GLP-1R wt versus
C438A plasma membrane recycling in INS-1 832/3 GLP-1R−/− (H) and MIN6B1 GLP-1R−/−
(I) cells expressing either wt or C438A mutant SNAP-GLP-1R. Cells were stimulated with 100
nM exendin-4 for 1 h to allow for maximal internalization of the receptor, followed by washout
and a further 3-h incubation with 10 μM of the GLP-1R antagonist exendin(9–39) to allow for
recycled receptors to accumulate at the plasma membrane. Nuclei (DAPI), blue; size bars,
10 μm. (J) Wt or C438A SNAP-GLP-1R internalization responses at indicated dose of exen-
din-4 in INS-1 832/3 GLP-1R−/− with stable SNAP-GLP-1R wt or C438A expression, measured
by DERET and expressed as fold increase from baseline, n = 5, “ns” indicates nonsignificant,
by statistical tests indicated in the text. Data are shown as mean ± SEM, with individual repli-
cates shown where relevant. Underlying raw data for all the panels included in this figure
can be found in S2 Data; uncropped blots from this figure can be found in S1 Raw Images.
DERET, diffusion-enhanced resonance energy transfer; FITC, fluorescein isothiocyanate;
GLP-1R, glucagon-like peptide-1 receptor; HEK293; human embryonic kidney 293; HTRF,
homogenous time-resolved fluorescence; TR-FRET, time-resolved Fo¨rster resonance energy
transfer; wt, wild-type.
(EPS)
S5 Fig. GIPR nanodomain clustering and palmitoylation. (A) Total input (“I”) and palmi-
toylated (“P”) SNAP-GIPR fractions from CHO-K1 cells stably expressing SNAP-GIPR and
treated with vehicle (“Veh”) or 100 nM GIP for 10 min. (B) SNAP-GIPR distribution within
TMFs, DSFs, and DRFs isolated from INS1 832/3 GIPR−/− cells transiently expressing SNAP--
GIPR after treatment with vehicle or 100 nM GIP for 5 min. (C) Comparison of SNAP-GLP-
1R and SNAP-GIPR clustering, detected by HTRF, in transiently transfected HEK293 cells
treated with vehicle, GLP-1 (100 nM), or GIP (100 nM) as indicated, n = 3; error bars have
been omitted for clarity. Parallel measurement of receptor surface expression by Lumi4-Tb
labeling and normalization to cell count also shown, paired t test. (D) Internalization of
SNAP-GIPR in INS-1 823/3 cells expressing SNAP-GIPR and labeled for 30 min with
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SNAP-Surface 549 (red) followed by treatment with and without 10 mM MβCD for 1 h before
stimulation with 100 nM GIP for 1 h. Nuclei (DAPI), blue; size bars, 10 μm, “ns” indicates
nonsignificant. Data are mean ± SEM. Underlying raw data for all the panels included in this
figure can be found in S2 Data; uncropped blots from this figure can be found in S1 Raw
Images. CHO, Chinese hamster ovary; DRF, detergent-resistant fraction; DSF, detergent-solu-
ble fraction; GIP, glucose-dependent insulinotropic polypeptide; GIPR, GIP receptor; GLP-
1R, glucagon-like peptide-1 receptor; HTRF, homogenous time-resolved fluorescence; MβCD,
methyl-β-cyclodextrin; TMF, total membrane fraction.
(EPS)
S6 Fig. Biased agonist effects on GLP-1R nanodomain segregation and clustering—Extra
data. (A) Kinetic traces of NR12S FRET in HEK293 SNAP-GLP-1R cells treated with the indi-
cated agonist (100 nM), expressed as ratio of signals at 570 nm to 490 nm, representing Lo
signal, or at 570 nm to 490 nm, representing Ld signal, and normalized to individual well base-
line, n = 6, paired t tests comparing plateau determined from one-phase association fits. (B)
Alternative analysis of data shown in (A), with AUC calculated from ratio of 570 and 610 sig-
nals, randomized block one-way ANOVA with Tukey’s test. (C) SNAP-GLP-1R internaliza-
tion responses at indicated dose of each agonist in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R
cells, measured by DERET and expressed as fold increase from baseline, n = 5. (D) Dose-
response analysis of data shown in (C), with each agonist dose represented by AUC, 4-parame-
ter logistic fit of pooled data shown. (E) SNAP-GLP-1R clustering responses at indicated dose
of each agonist in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells, measured by HTRF and
expressed as fold increase from baseline, n = 5. (F) Representative trajectories obtained during
single-molecule SNAP-GLP-1R tracking, shown as MSD over time and classified into four dif-
ferent groups (immobile, subdiffusion, normal diffusion, and superdiffusion), based on their
diffusion properties. �p< 0.05, ��p< 0.01, “ns” indicates nonsignificant by statistical test indi-
cated in the text. Data are shown as mean ± SEM. Underlying raw data used in S6F panel can
be downloaded from: https://doi.org/10.6084/m9.figshare.c.4592000; underlying raw data for
all other panels included in this figure can be found in S2 Data, and a dose-response summary
for this figure is included in S7 Table. AUC, area under the curve; DERET, diffusion-enhanced
resonance energy transfer; FRET, Fo¨rster resonance energy transfer; GLP-1R, glucagon-like
peptide-1 receptor; HEK293, human embryonic kidney 293; HTRF, homogenous time-
resolved fluorescence; Ld, liquid-disordered; Lo, liquid-ordered; MSD, mean squared displace-
ment.
(EPS)
S7 Fig. Biased agonist effects on GLP-1R nanodomain signaling—Extra data. (A) FRET
traces with the indicated biosensors and agonists, normalized to individual well baseline, in
CHO-SNAP-GLP-1R cells, n = 5 for each. (B) Dose-response curves constructed from data
shown in (A) for TEpacVV, AKAR4-NES and AKAR4-Lyn. For AKAR4-NES, signals have
been combined into 6-min bins to improve precision and named according to the midpoint
of each period, 3-parameter fits of pooled data shown. (C) TR-FRET kinetic binding data for
exendin-4-K12-FITC and exendin-phe1-K12-FITC in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R
cells with or without prior cholesterol depletion with MβCD (10 mM, 45 min), n = 7. (D) Asso-
ciation rate (kon), dissociation rate (koff), and equilibrium dissociation (Kd) constants derived
from (C), 2-way repeat-measures ANOVA with Sidak’s test comparing ± MβCD. �p< 0.05,
“ns” indicates nonsignificant by statistical test indicated in the text. Data are shown as
mean ± SEM, with individual replicates shown where relevant. Underlying raw data for all the
panels included in this figure can be found in S2 Data, and a dose-response summary for this
figure is included in S4 Table. CHO, Chinese hamster ovary; FITC, fluorescein isothiocyanate;
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FRET, Fo¨rster resonance energy transfer; GLP-1R, glucagon-like peptide-1 receptor; MβCD,
methyl-β-cyclodextrin; TR-FRET, time-resolved FRET.
(EPS)
S8 Fig. Effect of BETP on exendin-phe1 binding affinity and nanodomain signaling—
Extra data. (A) TR-FRET kinetic binding data for exendin-4-K12-FITC and exendin-
phe1-K12-FITC in INS-1 832/3 GLP-1R−/− SNAP-GLP-1R cells cotreated with or without
BETP (10 μM), n = 5. (B) Association (kon) and dissociation (koff) rate constants derived from
(A), 2-way repeat-measures ANOVA with Sidak’s test comparing ± BETP. (C) Effect of BETP
(10 μM) on exendin-phe1-induced β-arrestin-2 recruitment in PathHunter GLP-1R cells,
30-min incubation, 4-parameter fit of pooled data shown, n = 3. �p< 0.05, “ns” indicates non-
significant by statistical test indicated in the text. Data are shown as mean ± SEM, with individ-
ual replicates shown where relevant. Underlying raw data for all the panels included in this
figure can be found in S2 Data. BETP, 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoro-
methyl)pyrimidine; FITC, fluorescein isothiocyanate; GLP-1R, glucagon-like peptide-1 recep-
tor; TR-FRET, time-resolved Fo¨rster resonance energy transfer.
(EPS)
S1 Table. Dose-response summary for Fig 2 data.
(XLSX)
S2 Table. Dose-response summary for Fig 3 data.
(XLSX)
S3 Table. Dose-response summary for Fig 5 data.
(XLSX)
S4 Table. Dose-response summary for Fig 6 and S7 Fig data.
(XLSX)
S5 Table. Dose-response summary for Fig 7 data.
(XLSX)
S6 Table. Dose-response summary for S2 Fig data.
(XLSX)
S7 Table. Dose-response summary for S6 Fig data.
(XLSX)
S1 Movie. Time-lapse confocal microscopy of CHO SNAP-GLP-1R cells labeled with
SNAP-Surface 549 for 30 min and treated with vehicle for 1 h before stimulation with 100
nM exendin-4. CHO, Chinese hamster ovary; GLP-1R, glucagon-like peptide-1 receptor.
(AVI)
S2 Movie. Time-lapse confocal microscopy of CHO SNAP-GLP-1R cells labeled with
SNAP-Surface 549 for 30 min and treated with 10 mM MβCD for 1 h before stimulation
with 100 nM exendin-4. CHO, Chinese hamster ovary; GLP-1R, glucagon-like peptide-1
receptor; MβCD, methyl-β-cyclodextrin.
(AVI)
S3 Movie. Time-lapse confocal microscopy of INS-1 832/3 GLP-1R−/− cells stably express-
ing wild-type SNAP-GLP-1R following labeling with SNAP-Surface 549 for 30 min and
stimulation with 100 nM exendin-4. GLP-1R, glucagon-like peptide-1 receptor.
(AVI)
Agonist-induced GLP-1R–nanodomain interactions in beta cells
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000097 August 20, 2019 33 / 40
S4 Movie. Time-lapse confocal microscopy of INS-1 832/3 GLP-1R−/− cells stably express-
ing C438A SNAP-GLP-1R following labeling with SNAP-Surface 549 for 30 min and stim-
ulation with 100 nM exendin-4. GLP-1R, glucagon-like peptide-1 receptor.
(AVI)
S5 Movie. Single-molecule TIRF videomicroscopy recorded in CHO-K1 cells transiently
expressing SNAP-GLP-1R labeled with SNAP-Surface 549, vehicle conditions, including
overlaid individual trajectories (blue). CHO, Chinese hamster ovary; GLP-1R, glucagon-like
peptide-1 receptor; TIRF, total internal reflection fluorescence.
(M4V)
S6 Movie. Single-molecule TIRF videomicroscopy recorded in CHO-K1 cells transiently
expressing SNAP-GLP-1R labeled with SNAP-Surface 549, stimulated with 100 nM exen-
din-4, including overlaid individual trajectories (blue). CHO, Chinese hamster ovary; GLP-
1R, glucagon-like peptide-1 receptor; TIRF, total internal reflection fluorescence.
(M4V)
S7 Movie. Single-molecule TIRF videomicroscopy recorded in CHO-K1 cells transiently
expressing SNAP-GLP-1R labeled with SNAP-Surface 549, stimulated with 100 nM exen-
din-phe1, including overlaid individual trajectories (blue). CHO, Chinese hamster ovary;
GLP-1R, glucagon-like peptide-1 receptor; TIRF, total internal reflection fluorescence.
(M4V)
S8 Movie. Single-molecule TIRF videomicroscopy recorded in CHO-K1 cells transiently
expressing SNAP-GLP-1R labeled with SNAP-Surface 549, stimulated with 100 nM exen-
din-asp3, including overlaid individual trajectories (blue). CHO, Chinese hamster ovary;
GLP-1R, glucagon-like peptide-1 receptor; TIRF, total internal reflection fluorescence.
(M4V)
S1 Raw Images. Uncropped blots shown throughout the paper.
(EPS)
S1 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data
for all panels in Figs 1–8.
(XLSX)
S2 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data
for all panels in S1–S8 Figs.
(XLSX)
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